The Plasma Membrane Calcium ATPases and Their Role as Major New Players in Human Disease. by Stafford, Nicholas et al.
THE PLASMA MEMBRANE CALCIUM ATPASES AND
THEIR ROLE AS MAJOR NEW PLAYERS IN HUMAN
DISEASE
Nicholas Stafford, Claire Wilson, Delvac Oceandy, Ludwig Neyses, and Elizabeth J. Cartwright
Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
L
Stafford N, Wilson C, Oceandy D, Neyses L, Cartwright EJ. The Plasma Mem-
brane Calcium ATPases and Their Role as Major New Players in Human Disease.
Physiol Rev 97: 1089–1125, 2017. Published May 31, 2017; doi:10.1152/phys-
rev.00028.2016.—The Ca2 extrusion function of the four mammalian isoforms of
the plasma membrane calcium ATPases (PMCAs) is well established. There is also
ever-increasing detail known of their roles in global and local Ca2 homeostasis and intracellular
Ca2 signaling in a wide variety of cell types and tissues. It is becoming clear that the spatiotem-
poral patterns of expression of the PMCAs and the fact that their abundances and relative
expression levels vary from cell type to cell type both reflect and impact on their specific functions
in these cells. Over recent years it has become increasingly apparent that these genes have
potentially significant roles in human health and disease, with PMCAs1-4 being associated with
cardiovascular diseases, deafness, autism, ataxia, adenoma, and malarial resistance. This review
will bring together evidence of the variety of tissue-specific functions of PMCAs and will highlight the
roles these genes play in regulating normal physiological functions and the considerable impact the
genes have on human disease.
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I. INTRODUCTION
The presence of an ATP-dependent Ca2 transporter lo-
cated in the plasma membrane was first identified in eryth-
rocytes half a century ago (327). The plasma membrane
calciumATPase (PMCA) has since been classified as amem-
ber of the P-type transport ATPase family, due to the cova-
lent intermediate state that is formed upon phosphorylation
of a highly conserved aspartate residue during its catalytic
cycle (285). The pumps are high affinity (0.2–0.5Munder
optimal conditions) Ca2 extruders, binding a single intra-
cellular Ca2 ion which is then deposited to the extracellu-
lar space following conformational changes which first al-
low transport of the ion through the plasma membrane and
finally dissociation from the pump through lowering its
Ca2 affinity (44, 225). This means that compared with the
related ATPase of the sarco(endo)plasmic reticulum
(SERCA), the PMCA has a lower capacity for Ca2 clear-
ance, removing only one Ca2 ion per ATPmolecule hydro-
lyzed as opposed to two (143). PMCA’s export of Ca2
occurs in conjunction with the import of one or more pro-
tons (H), with reports ranging from an electrogenic1 to
~3 H per Ca2 in barnacle skeletal muscle to an electro-
neutral 1Ca2:2H stoichiometry in human erythrocyte
membrane preparations and snail neurons (93, 264, 371).
There are four known PMCA isoforms, encoded by sepa-
rate genes ATP2B1-4 located at human chromosomal loci
12q21-q23, 3p25-p26, Xq28, and 1q25-q32, respectively
(358). In the mouse, a model which has been extensively
used to understand the functional roles of the PMCAs, these
four genes are located on chromosomes 10, 6, X, and 1,
respectively. In both humans and mouse, the PMCAs 1–4
exhibit differential spatial patterns of expression, with iso-
forms 1 and 4 being more or less ubiquitous, while PMCA2
and 3 expression is restricted to specific cell types, most
notably in the nervous system. In addition, a total of over 25
splice variants have been identified, including the more or
less ubiquitous full-length “b” variants deemed to play
housekeeping functions, and many others which show cell
specific distributions (147, 353, 358). This has led to the
consensus that each isoform and variant may perform
unique functions.
II. PMCAS: THE RELATIONSHIP BETWEEN
STRUCTURE AND FUNCTION
This review article focuses its attention on the PMCAs in
human health and disease and our current understanding of
their physiological and pathophysiological roles. By way of
introducing the PMCAs, we provide an overview of the
structure of the PMCA isoforms and their regulation, but
for more extensive and detailed information, we refer the
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reader to a number of excellent published reviews (51, 94,
358).
A. The Structure of PMCA
The general structure of the PMCA, like other members of
the P-type ATPase family, consists of 10 hydrophobic trans-
membrane (TM) domains flanked by cytosolic NH2 and
COOH terminals, and with two large intracellular loops
(94, 358). More specifically, the PMCAs belong to the type
II subset of P-type ATPases which include a number of
proteins of physiological/pathophysiological importance in
vertebrates due to their roles in themovement of a variety of
ions across membranes. The NH2 terminal of the PMCA
contains the most variation among isoforms in its 80–90
amino acids. The two intracellular loops span TM domains
2–3 and 4–5, and each contains an autoinhibitory region
that interacts with a calmodulin-binding site located on the
long COOH terminal rendering the PMCA in a closed con-
formation in the absence of calmodulin and greatly reduc-
ing its Ca2 affinity (116, 117). The second intracellular
loop contains the catalytic core of the pump, featuring con-
served aspartate and lysine residues critical for catalytic
phosphorylation and ATP binding, respectively.
The determination of the complete nucleotide sequence
for the PMCA by two groups in the late 1980s began to
clarify the structure of the enzyme (346, 387). The gene
products among these isoforms share ~75–85% identity,
while ~85–90% of the primary sequence is conserved
(356). Importantly, rodent and human isoforms share
~99% sequence homology making rodents a suitable
model in which to study PMCA function. The regions of
the PMCA displaying least identity among isoforms are
the NH2 and COOH terminals (58, 357), which may be
of note as the COOH terminal is especially rich in inter-
action partners (see sect. IID).
B. Regulation of PMCA Activity
The major regulator of pump activity is calmodulin (CaM),
which upon binding to its domain releases autoinhibition
and raises pump Ca2 affinity to sub-micromolar levels
rendering it active at cellular concentrations and increasing
pump activity four- to sixfold (107, 112). CaM affinity is 5-
to 10-fold higher in neuronal isoforms PMCA2 and 3 com-
pared with the ubiquitous PMCA1 and 4 (44), while
PMCA2 displays unusually high basal ATPase activity in
the absence of CaM compared with other isoforms (107).
Interestingly, there is evidence that the erythrocyte PMCA
exists as both a CaM-activated monomer as well as in a
Ca2-dependent dimeric formwhich is fully activated in the
absence of CaM (64, 190, 191). To date, there are no re-
ports as to whether the self-activated oligomeric form is
present in other cell types.
Further mediators of pump activation have also been iden-
tified including the action of acidic phospholipids, unsatu-
rated fatty acids, and trypsin-mediated partial proteolysis
of the enzyme (263). In addition, a rise in basal activity has
been witnessed upon phosphorylation of the PMCAs by
protein kinase C (PKC) (113) and, in the case of PMCA1,
protein kinase A (PKA) (142).
C. PMCAs and Regulation of Global and
Local Intracellular Ca2
Every cell type has unique requirements for optimal Ca2
homeostasis to perform their respective physiological func-
tions. This can range from the maintenance of a low resting
intracellular Ca2 concentration ([Ca2]i) to prevent the
activation of Ca2-mediated cell death to dynamic control
of beat-to-beat Ca2 levels in cardiomyocytes enabling
muscle contraction and relaxation. In nonexcitable cells
where the resting intracellular Ca2 levels remain low, the
PMCA is generally the principal Ca2 removal system
(423); however, excitable cells such as myocytes and neu-
rons with their more complex needs for Ca2 extrusion
demand higher capacity systems for cytosolic Ca2 clear-
ance. In excitable cells, the three main pathways for re-
moval of cytosolic Ca2 are via reuptake into the sarco(en-
do)plasmic reticulum via SERCA (221), and extrusion from
the cell via the PMCA and the high capacity sodium-cal-
cium exchanger (NCX) (45, 96), as illustrated in FIGURE 1A.
The relative contributions of these three pathways to Ca2
clearance vary depending on cell type. In bladder smooth
muscle for example, these are roughly 2:1:1 in favor of the
NCX (138), whereas in cardiomyocytes, 70–92% of Ca2
(dependent on species) is returned to the internal store via
SERCA with the remainder largely extruded via the NCX,
leaving the PMCA along with a small amount of mitochon-
drial reuptake, together coined the “slow systems,” to con-
tribute little more than 1% to global Ca2 clearance (26).
The PMCA is not only involved in global Ca2 homeostasis
however, but also in the regulation of local intracellular
Ca2 dynamics. Similarly to transient receptor potential
canonical (TRPC) channels and inositol 1,4,5-trisphos-
phate receptors (InsP3Rs), which have been shown to acti-
vate Ca2-dependent effectors through generating high
Ca2 microdomains at the subplasmalemmal and perinu-
clear compartments, respectively (104, 406), the PMCA is
able to regulate downstream signaling pathways. In the case
of the PMCA, this is achieved through pump activity low-
ering the [Ca2] in its microdomain, thereby negatively reg-
ulating Ca2-dependent interaction partners as illustrated
in FIGURE 1B.
To gain an understanding of how the PMCA can influence
local Ca2 dynamics and to directly monitor PMCA activ-
ity, we have recently developed a novel fusion protein by
cloning the genetically encoded Ca2 indicator GCaMP2 to
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the NH2 terminal of PMCA4. Upon transfection into car-
diomyocytes, the PMCA4-GCaMP2 fusion protein was
able to detect Ca2 oscillations in the subsarcolemmal com-
partment which could be inhibited by specific pharmaco-
logical blockade of PMCA4, thus providing us with a tool
to assess Ca2 dynamics in the local vicinity of PMCA4
(241). It is clear therefore that the PMCAs can regulate both
global and local intracellular Ca2 levels depending on tis-
sue type and PMCA isoform, while through the import of
H and hydrolysis of ATP they may also influence subplas-
malemmal pH and ATP concentration (85, 93, 372). This
regulation of local Ca2 lends itself to the PMCA being a
major mediator of Ca2-dependent signaling events (59,
267) as we will describe in the following section.
D. PMCAs as Signaling Molecules via
Interactions With Protein Partners
Amidst large fluctuations in global Ca2 during excitation-
contraction coupling, excitable cells retain the ability to
utilize Ca2 as a second messenger in many signaling path-
ways involved in both normal physiological function and in
disease progression (126). Over recent years the PMCA has
emerged as a significant regulator of Ca2-dependent sig-
naling, through protein-protein interactions and compart-
mentalization of the signal in the subplasmalemmal mi-
crodomain (267). A possible role in signal transduction was
suggested based on evidence that PMCA4 is localized in
protein-rich signaling hubs termed caveolae (128).
In subsequent years, our group and others have identified
many PMCA interaction partners, some of which are com-
mon to all PMCAs and others unique to particular isoforms
(FIGURE 2). Many of these interactions occur at a PDZ
ligand-binding domain located at the terminal end of
the carboxyl tail. Interacting partners at this domain in-
clude members of the membrane-associated guanylate ki-
nase (MAGUK) family, calcium/calmodulin-dependent ser-
ine protein kinase (CASK), LIM family protein CLP36,
homer protein Ania-3, PMCA-interacting single-PDZ pro-
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FIGURE 1. A: cartoon illustrating global Ca2 regulation in an excitable cell. The sources of Ca2 entry to the
cytosol and associated rise in global intracellular Ca2 are highlighted in blue, while routes for cytosolic Ca2
clearance and associated decay phase of the global transient are highlighted in red. B: diagram demonstrating
regulation of local Ca2 and Ca2-dependent signaling by PMCA. PMCA activity generates a low Ca2
microdomain in its vicinity, negatively regulating Ca2-dependent binding partners by attracting them to its
locale in caveolae, thereby influencing downstream signaling. VOCC, voltage-operated Ca2 channel; ROCC,
receptor-operated Ca2 channel; IP3R, inositol trisphosphate receptor; RyR, ryanodine receptor; SERCA,
sarco(endo)plasmic reticulum Ca2-ATPase; PMCA, plasma membrane Ca2-ATPase; NCX, Na/Ca2
exchanger.
CLP36
CASK
Catalytic
domain
aa 65
2-840
aa 428-651
MAGUKs
NHERF2
14-3-3ε
RASSF1Aα1-syntrophin
nNOSeNOS
CnA
N
C
Ania3
PISP
1 2 3 4 5 6 7 8 9 10
Extracellular
Intracellular
CaM-B
D
PD
Z-
BD
FIGURE 2. Schematic illustrating general PMCA structure, con-
sisting of 10 transmembrane (TM) domains. The intracellular loop
connecting TM 4 and 5 contains the catalytic core with phosphory-
lation and ATP binding sites. PMCA interaction partners are shown,
with arrows detailing to which regions they bind. CnA, calcineurin A;
eNOS, endothelial nitric oxide synthase; RASSF1A, Ras-associated
factor 1A; NHERF2, Na/H exchanger regulatory factor 2; CASK,
calcium/calmodulin-dependent serine protein kinase; MAGUK,
membrane-associated guanylate kinase; PISP, PMCA-interacting
single-PDZ protein; nNOS, neuronal nitric oxide synthase; PDZ-BD,
PDZ protein-binding domain; CaM-BD, calmodulin-binding domain.
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tein (PISP), Na/H exchanger regulatory factor 2 (NH-
ERF2), and neuronal nitric oxide synthase (nNOS) (39, 91,
92, 137, 182, 334, 335, 339). We have found the PMCA4-
nNOS interaction to occur in a macromolecular complex
with -1 syntrophin and dystrophin, through binding a
linker region on -1 syntrophin to the PMCA’s second in-
tracellular loop (395). Further interactions in this catalytic
region of the PMCA occur with the Ca2-dependent phos-
phatase calcineurin, the tumor suppressor Ras-associated
factor 1A (RASSF1A), and endothelial nitric oxide synthase
(eNOS) (13, 46, 158). Meanwhile, isoform  of the traffick-
ing protein 14-3-3 has been found to associate with
PMCA4’s NH2-terminal region (312). As we describe later
in this review, some of these interactions have now been
well characterized to be of functional significance, in par-
ticular those between PMCA and nNOS in the cardiovas-
cular system, and PMCA and calcineurin in cardiovascular
and breast cancer cells (61, 160).
It may in part be through the individualities of these inter-
actions that isoforms can perform specific functions. For
example, in identifying an inhibitory interaction between
14-3-3 and PMCA4, Carafoli and colleagues noted no
association with PMCA2 (312). Similarly, while Strehler
and colleagues found both isoforms 2 and 4 to interact with
MAGUK family proteins, some family members bound se-
lectively to PMCA4 (92), while NHERF2 interacts only
with PMCA2 (91). These differences in the biochemical
properties of the pumps mean that the various PMCA iso-
forms perform cell-specific roles, not only in health but also
in human pathophysiology. The remainder of this review
will focus on the tissue-specific physiological roles and dis-
ease associations of the PMCA pumps.
III. PMCA AND ITS ASSOCIATIONS WITH
HUMAN DISEASE
In recent years, the relevance of the PMCA in a number of
human disease processes has come to light. Through exam-
ination of whole genomes among populations it is now
possible to identify particular genetic variants associated
with a certain disease. Following extensive data analysis,
genome-wide association studies (GWAS) can detect partic-
ular disease-causing single nucleotide polymorphisms
(SNPs) located within specific loci in the genome. Genetic
mutations in the genes encoding each PMCA isoform have
now been associated with human disease (Table 1 and FIG-
URE 3), highlighting the significance of this family of Ca2
pumps in human health and disease.
A. PMCA1, Hypertension, and
Cardiovascular Disease
Worldwide more people die from cardiovascular diseases
(CVD) than any other cause. Currently, over 30% of all
deaths are attributed to CVD, and despite the size of the
ongoing research focus, the World Health Organisation
predicts that by 2030 the number of people that will die
annually from this group of diseases will rise to ~22 million
(1). Hypertension, which is a major risk factor for cardio-
vascular disease, affects ~30% of the adult population
worldwide (201) and has long been thought to be influ-
enced by genetic factors as well as environmental ones. In
the past 5 years, GWAS of systolic and diastolic blood pres-
sure, as well as hypertension in general, have reported the
most significant SNPs associated with these diseases to oc-
cur at multiple loci in and around ATP2B1, the gene which
encodes PMCA1 (76, 173, 178, 206, 366). This finding is
consistent among multiple ethnicities including those of
East Asian (Japanese, Korean and Chinese), South Asian,
and European origin; however, the two studies carried out
in African-American populations showed no association
between ATP2B1 and hypertension. Although the effects
of ATP2B1 variants on systolic and diastolic blood pres-
sure are small at around 1 mmHg (105), Levy et al. (206)
predicted the risk of developing hypertension to increase
by 17 and 37% dependent on whether one or two respec-
tive alleles are affected. This finding of an association
between ATP2B1 and hypertension is not just limited to
adults as one study has determined that the ATP2B1 SNP
rs2681472 is associated with an increased risk of hyper-
tension in Chinese children (407), while the same SNP
also predisposes Chinese women to early-onset pre-
eclampsia during pregnancy (389). Using a gene-centric
array in which ~50,000 SNPs in 2,100 genes previously
implicated in cardiovascular, metabolic, and inflamma-
tory processes, Fontana et al. (124) demonstrated a
strong association between SNP rs12817819 in ATP2B1
and resistant hypertension, a condition in which raised
blood pressure is not controlled despite the use of at least
three antihypertensive drugs.
It is beginning to emerge that it may be a reduction in the
expression of ATP2B1 which leads to raised blood pres-
sure. Human umbilical artery smooth muscle cells carrying
the risk allele of the ATP2B1 SNP rs11105378 were found
to have reduced ATP2B1 mRNA expression (364). Studies
in transgenic mice are also beginning to provide functional
evidence of the role of ATP2B1 in blood pressure control,
with PMCA1 silencing leading to the development of hy-
pertension associated with an increase in intracellular Ca2
and vascular remodeling (187, 343).
Hypertension is not the only cardiovascular disease to be
linked by genetic association and candidate gene studies
with ATP2B1. A number of studies have now identified
SNPs in the ATP2B1 locus to carry increased risk of
developing coronary artery disease in Asian and Cauca-
sian populations (219, 367, 394) and myocardial infarc-
tion (119), while mutations also associate with several
cardiovascular disease risk factors such as salt sensitivity
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and coronary artery calcification in chronic kidney dis-
ease (119, 309).
These data combined demonstrate the importance of
PMCA1 in human health and its potential role in cardio-
vascular disease, and together suggest that PMCA1 may
play a critical role in Ca2 clearance and homeostasis in
vascular smooth muscle and/or endothelial cells.
B. PMCA2, Hereditary Deafness,
and Autism
Hearing loss is known to be caused by both genetic and
environmental factors and likely often a combination of the
two. One of many genes that have been associated with
deafness is ATP2B2, the gene that encodes PMCA2. Muta-
tions in PMCA2 have been identified by two studies of
Table 1. Reported SNPs in ATP2B isoforms and their association with disease phenotypes
SNP Disease Association Ethnicity Reference Nos.
ATP2B1-PMCA1
rs1401982 Hypertension, SBP, DBP, arterial stiffness Chinese 391
rs2070759 Hypertension Japanese 364
rs2681472 Hypertension, SBP, DBP Japanese 366
SBP, DBP European 206
Salt sensitivity Korean 309
Preeclampsia Han Chinese 389
Coronary artery disease East Asian 367
rs2681492 SBP, DBP European 206
Hypertension, SBP, DBP, arterial stiffness Chinese 391
MAP, PP East Asian 180
rs7136259 Coronary artery disease Han Chinese 219
rs10858911 Hypertension, SBP, DBP, arterial stiffness Chinese 391
rs11105354 SBP, DBP European 206
Hypertension, SBP, DBP, MAP European 173
Coronary artery calcification in chronic kidney disease European/African 119
Myocardial infarction European/African 119
rs11105378 Hypertension Japanese 364
rs12817819 Resistant hypertension (in patient groups with CAD or
ischemic HD)
European American and Hispanics 124
rs17249754 Hypertension, SBP, DBP, arterial stiffness Chinese 391
Hypertension, SBP, DBP East Asian, South Asian, African 105
Hypertension, SBP, DBP Korean 162
SBP, DBP Asian 76
Hypertension Chinese children 407
Hypertension, SBP, DBP Chinese 220
MAP, PP East Asian 180
Obesity and hypertension in children Han Chinese 408
Coronary artery disease European 213
Hyperlipidemia and diabetes Korean 152
ATP2B2-PMCA2
rs35678 Autism European (Italian) 52
rs241509 Autism spectrum disorders European (Italian) 296
rs3774179 Autism Han Chinese 414
ATP2B4 - PMCA4
rs4951074 Malaria in children African 373
Severe malaria/cerebral malaria/severe malarial anemia African 314a
rs10900585 Malaria in pregnancy African 21
Malaria in children African 373
Severe malaria/cerebral malaria/severe malarial anemia African 314a
SNP, single nucleotide polymorphism; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; CAD,
coronary artery disease; HD, heart disease.
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families with hereditary hearing loss (123, 336). While the
mutations identified in each family were different, in both
cases the mutation seems to potentiate the effects of a mu-
tation in the cadherin23 gene, resulting in severe hearing
impairment. Studies in a number of mouse mutants appear
to corroborate the fact that PMCA2 is essential for normal
hearing function: the first of these was a mouse line known
as “deafwaddler,” which as the name suggests has both
deafness and motor imbalance. The mutation, which arose
spontaneously, leads to a single point mutation in PMCA2
resulting in an amino acid change which affects sensory
transduction in hair cells of the inner ear, in addition to
neurotransmitter release from the basolateral membrane
(355). A second spontaneous mutant known as “wriggle
mouse sagami” also carries a PMCA2 point mutation,
which differs from that of deafwaddler, and again results in
hearing loss (365). Over the subsequent years other spon-
taneous mutations were identified, a gene knockout was
generated, and a number of ethylnitrosourea (ENU) mu-
tagenesis screens were performed which identified muta-
tions in Atp2b2 leading to deafness (38, 192, 236, 350,
410). The most recent of these ENU mutagenesis screens
revealed two novel mutants of Atp2b2, one carrying a mu-
tation in the 10th transmembrane domain and the other
with a mutation in the catalytic core, both of which resulted
in mild to moderate, progressive hearing loss in the
heterozygous mutants and profound deafness in the ho-
mozygotes (56).
Recent links have also been made between PMCA2 and
autism as a result of GWAS and candidate gene studies.
Autism is a neurodevelopmental disorder with multiple
genetic causes and an extremely high level of heritability.
GWAS identified a number of chromosomal regions to
have linkage to autism, including the region 3p25, where
ATP2B2 (as well as a number of other genes) is located
(200, 235, 341). In a subsequent study comparing the
gene expression profiles of lymphoblasts from autistic
and nonaffected sibling pairs, ATP2B2 was the only gene
found to be differentially expressed of the 43 known
genes in the identified region at 3p25 (164). Using Inge-
nuity Pathway Analysis, Hu et al. (164) identified that
differential expression of ATP2B2 may affect nervous
system development and function via altering Purkinje
cell morphology, cerebellar development, or synapse bio-
genesis. Intracellular Ca2 levels and Ca2-signaling
pathways are indeed important in the regulation of neu-
ronal survival, differentiation, migration, and synapto-
genesis, and it is likely that perturbations in these pro-
cesses may play a role in the pathogenesis of autism spec-
trum disorders (193).
Based on this evidence, Carayol et al. (52) carried out a
family-based association study that identified a number of
SNPS in ATP2B2 as having a significant association with
autism in males only. Further studies have identified SNPs
in ATP2B2 as being associated with autism and autism
Autism
ATP2B2 ATP2B3
ATP2B1 ATP2B4
Hypertension
Pre-eclampsia
Salt sensitivity
Coronary artery disease
Myocardial infarction
Coronary artery calcification
Deafness
Cerebellar
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Aldosterone
producing
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paraplegia
FIGURE 3. Cartoon depicting the dis-
eases that have presently been found to be
associated with genetic variants of each of
the four PMCA isoforms in humans. Hu-
man disease associations of ATP2B1 are
shown in blue, ATP2B2 in green, ATP2B3
in gray, and ATP2B4 in pink.
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spectrum disorders in Italian families and in those of Han
Chinese descent (296, 414).
C. PMCA3, Cerebellar Ataxia, and Adenoma
ATP2B3 mutations have been linked to two separate dis-
eases affecting different organs. One was identified in a
family with X-linked cerebellar ataxia, where three out of
three descendants of a carrier female were found to be either
affected (males) or a carrier (female) (420). The mutation,
which was identified by exome sequencing, was found in
the calmodulin binding domain of PMCA3, which was
found in in vitro studies to impair Ca2 clearance in cell
culture. Calì et al. (50) have identified another mutation of
ATP2B3, which results in a missense mutation and im-
paired Ca2 extrusion, in a patient with cerebellar ataxia
and developmental delay. The patient not only carried a
PMCA3 mutation but also two mutations in LAMA1, the
gene encoding laminin 1, and it may be that the observed
disease phenotype is dependent on simultaneous mutations
in both of these genes.
Given the predominant expression of PMCA3 in the ner-
vous system, including the cerebellum where it has a role in
neuronal Ca2 homeostasis, the association with cerebellar
ataxia is not unexpected. However, what is more surprising
is that two novel ATP2B3 mutations have recently been
found in tissue from a number of aldosterone-producing
adenomas (APAs), a major factor in the development of
primary aldosteronism which is the most common cause of
secondary hypertension (27). Since Beuschlein et al.’s first
report in 2013 (27), ATP2B3 mutations have been identi-
fied in APAs present in western European, Japanese, Tai-
wanese, Chinese, and American populations occurring at
frequencies ranging from 0.6 to 9% (6, 102, 121, 186, 272,
330, 331, 396, 404, 422). With the exception of one Tai-
wanese patient who exhibited a Tyr410Asp substitution
(404), all mutations identified thus far involve the deletion
of one or more amino acids between Thr-423 and Leu-
433 lying in the M4 region of the plasma membrane,
believed to be important in Ca2 binding during its trans-
port to the extracellular space. Clinically APAs contain-
ing ATP2B3 mutations are associated with higher levels
of aldosterone secretion when compared with wild-type
APAs (27, 186, 397), most likely as a result of an ob-
served increase in aldosterone synthase CYP11B2 expres-
sion (250, 254, 396). Recently these associations have
been confirmed through the transfection of ATP2B3 car-
rying the common Leu425_Val426 deletion into adreno-
cortical NCI-H295R cells, resulting in impaired Ca2
clearance accompanied by elevated basal Ca2,
CYP11B2 expression, and aldosterone secretion (370). This
highlights a highly specialized function for this isoform in
nonneuronal tissue.
D. PMCA4, Malarial Resistance, and
Familial Spastic Paraplegia
The Ca2-ATPase of the membrane of erythrocytes was the
first to be characterized, and has since been found to consist
predominately of PMCA4 (352). Recently a GWAS identi-
fied a novel locus within ATP2B4 where several SNPs con-
ferred resistance to a severe form of malaria among children
in a West African population (373). One of the SNPs iden-
tified in this study was also shown to confer protection
against malaria and associated maternal anemia in preg-
nant Ghanaian women (21), which may make PMCA4 an
interesting target for anti-malarial medication (246). This
association between PMCA4 and malaria was strengthened
by the findings of a large multi-center study in which several
ATP2B4 SNPs were analyzed in ~12,000 cases of severe
malaria from 12 different locations in Africa, Asia, and
Oceania (224).
A single nucleotide variant of ATP2B4 which results in a
missense mutation has been found in a Chinese family with
familial spastic paraplegia, a disease leading to muscle
weakness and spasticity of the lower limbs (212). In a sub-
sequent study, the authors have demonstrated that this mu-
tation in ATP2B4 results in altered Ca2 homeostasis, per-
haps suggesting a link between disrupted Ca2 regulation
and familial spastic paraplegia (156).
IV. TISSUE-SPECIFIC FUNCTIONS OF
THE PMCAs
It can be said that PMCA is ubiquitously expressed, with all
cell types expressing at least one isoform of this gene family.
The level, localization, and temporal nature of the expres-
sion of the PMCAs likely reflect their specific functional
roles during embryonic development and in the adult in
both health and disease.
In situ hybridization has provided evidence that PMCA1 is
expressed by day 9.5 post coitum (pc) in the developing
mouse embryo and is abundant and ubiquitous thereafter,
although most concentrated in the heart, nervous system,
skeletal muscle, and intestine (415). All four isoforms are
expressed by day 12.5 pc, with PMCA2 confined to the
brain and PMCA3 to the nervous system, lung, and skeletal
muscle. PMCA4 expression is ubiquitous though less abun-
dant than PMCA1, with the strongest expression found in
the brain, bladder, heart, and spinal cord (415). The early
and widespread nature of PMCA1 expression has led to the
opinion that this isoform is the major housekeeping iso-
form.
The ubiquitous pattern of PMCA1 expression persists after
birth and throughout adulthood in both rat and human,
while PMCA4 is also present in most cells. The ratio of
PMCA1 expression to that of isoform 4 is roughly 2:1 in
PMCAs IN HUMAN DISEASE
1095Physiol Rev • VOL 97 • JULY 2017 • www.prv.org
 by 10.220.33.1 on June 20, 2017
http://physrev.physiology.org/
D
ow
nloaded from
 
human adult lung, liver, kidney, stomach, and skeletal mus-
cle (353). In the heart, however, the ratio between the two
isoforms is roughly 1:1. PMCA2 demonstrates a more spe-
cific expression pattern, being prominent in Purkinje and
inner ear cells, as well as in lactating mammary glands,
while isoform 3 expression is restricted largely to neurons in
the neonate and adult (358).
A. Role of PMCAs in the Development
of the Embryo
Of the two largely ubiquitously expressed isoforms of
PMCA (PMCA1 and 4), PMCA1 has been given the status
of the housekeeping isoform based on the fact that it is the
isoform to be expressed earliest in the development of the
embryo; that it is widely expressed in both the embryo and
the adult; and that its deletion leads to embryonic lethality.
Other than the fact that there are no live births of PMCA1
knockout mice, we currently know little of the role of
PMCA1 during development. The same is also true of the
other PMCA isoforms; PMCA2 and PMCA4 knockout
mice are viable, and while they are both expressed during
development, their role has not been studied and we know
even less of PMCA3 as a knockout mouse has never been
reported.
1. PMCA and the placenta
The transport of Ca2 frommother to baby via the placenta
is tightly regulated during pregnancy to ensure normal fetal
development and in particular skeletal mineralization.
PMCAs are among many Ca2 handling pumps, channels,
and exchangers that move Ca2 across the placenta. The
syncytiotrophoblast, which is a polarized epithelium with a
maternal microvillus membrane and a fetal-facing basal
membrane, is a critical site involved in this transfer of Ca2
from the maternal to the fetal circulation (290). During this
transepithelial transfer, Ca2 enters the syncytiotropho-
blast on the brush-border membrane via transient receptor
potential vanilloid (TRPV) channels, from where it is car-
ried to the fetal side of the syncytiotrophoblast by Ca2-
binding proteins, and then extruded by the PMCAs. The
importance of the PMCAs in this process is evident, as
ATP-dependent Ca2 transport increases linearly across the
syncytiotrophoblast basal membrane during the third tri-
mester of pregnancy in line with the demand for fetal skel-
etal mineralization (360), and the level of PMCA3 gene
expression correlates with the level of bone mineral content
in newborn babies (232).
Given this vital role in materno-fetal Ca2 transfer, it is no
surprise that alterations in PMCA activity and expression
have been witnessed in pregnancies complicated by a num-
ber of diseases. As already mentioned, the common SNP
rs2681472 in ATP2B1 has been associated with the risk of
early-onset preeclampsia, a leading cause of maternal and
fetal mortality, preterm labor, and intrauterine growth restric-
tion present in ~5% of pregnancies (389). Myometrial and
subcutaneous resistance arteries from preeclamptic women
display impaired relaxation and PMCA attributable Ca2
clearance (398) while preeclamptic myometrium and syncy-
tiotrophoblasts display a 50% reduction in PMCA activity
and reduced PMCA1 and 4 expression (57, 145). In addition
to changes during preeclampsia, altered ATP-dependent Ca2
transport has also been witnessed in the placenta in pregnan-
cies complicated by intrauterine growth restriction and insu-
lin-dependent diabetes mellitus (359). These observations
highlight the importance of the PMCA in tightly regulating
Ca2 transport between the mother and fetus.
2. PMCA and the spermatozoa
As in many cell types, Ca2 is essential for the regulation of
a number of functions of the spermatozoa, including motil-
ity, the acrosome reaction, and fusion of sperm and egg
membranes (83). The PMCA, by acting as an extrusion
pump, is known to provide tight control of intracellular
Ca2 levels which is required for normal sperm function
and hence male fertility. While both PMCA1 and PMCA4
are expressed in spermatozoa, it has been shown that
PMCA4 is the predominant isoform and is localized to the
principal piece of the sperm tail (269). More recently it has
been shown that in mouse sperm both major PMCA4 splice
variants (PMCA4a and PMCA4b) are expressed through-
out the sperm maturation process (283). Gene knockout
studies have provided very clear evidence of the functional role
PMCA4 has in spermmotility. Two separatemousemodels in
which PMCA4has been deleted, our ownmodelwhich carries
a null deletion resulting in lack of expression of all PMCA4
splice variants (332), and that of Okunade et al. (269) which
produces a functionally inactive mutant protein, both lead to
male infertility as a result of impaired motility. Homozygous
PMCA4 knockout mice are born at the expected Mendelian
ratio whenmice carrying a heterozygous PMCA4 deletion are
bred; however, breeding ofmale and female PMCA4KOmice
did not result in any pups being born, even though mating
behaviorwas normal. Investigations revealed sperm and testes
morphology were normal, but assessment of parameters of
motility showed a lack of progressive, directional, and hyper-
activated motility (269, 332). Given that PMCA1 knockout
mice are embryonic lethal, it cannot be ruled out that PMCA1
also has an important role in spermmotility, butmice carrying
a heterozygous deletion of PMCA1 are not known to have
impaired fertility (269).
B. Role of PMCAs in the Sensory Systems
Due to the nervous system being one of the only areas of the
human body where all four PMCA isoforms are expressed,
numerous studies have looked at the role of PMCA in neuro-
nal health and disease. As previously mentioned, PMCA2 and
PMCA3 have been established as being clinically related to
STAFFORD ET AL.
1096 Physiol Rev • VOL 97 • JULY 2017 • www.prv.org
 by 10.220.33.1 on June 20, 2017
http://physrev.physiology.org/
D
ow
nloaded from
 
deafness and cerebellar ataxia, respectively (134, 420). Fur-
thermore, PMCA has been reported to be involved in other
sensory roles such as vision as well as numerous neuronal
conditions associated with balance dysfunction and aging.
1. PMCA and the eye
PMCA isoform expression has been reported in various re-
gions of the eye including lens epithelial cells (all PMCA iso-
forms), the corneal epithelium (all isoforms), lamina cribrosa
cells of the optic nerve head (PMCA1 and 4), various cell types
of the inner retina (all PMCA isoforms), and the photoreceptors
(PMCA1, 2, and 4) (195, 226, 237, 369). For ease of navigation,
the macrostructure of the eye is depicted in FIGURE 4A.
Themaintenance of low [Ca2]i levels in the lens against the
very high concentration in the surrounding aqueous humor
requires tight regulation over Ca2 homeostasis, and the
PMCAs are among the mechanisms involved in ensuring
this control, thus preventing lens opacity (310) (FIGURE 4B).
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The PMCA predominantly removes Ca2 from lens epithe-
lial cells, whereas expression is absent from fiber cells where
the NCX takes on increased importance. It has been known
for many years that intracellular Ca2 is increased in cata-
ractous lenses (100), and it is not surprising therefore that
Ca2-ATPase activity is reduced by 50% in lenses from
cataractous donors (284) despite a possibly compensatory
upregulation in PMCA2 expression (227). Further evidence
for a potentially protective role of the PMCA in cataract
prevention has been found in cultured human lens epithelial
cells exposed to two major factors involved in cataract de-
velopment: an increase in PMCA1 expression was observed
in response to raised [Ca2]i (228), and both PMCA1 and 2
expression increased in response to oxidative stress (229).
Altered PMCA expression has also been witnessed in glial
fibrillary acid-negative protein lamina cribrosa cells of the
optic nerve head obtained from donors with glaucoma,
which play an integral role in characteristic extracellular
matrix remodelling during this condition. Both PMCA1
and 4 expression were found to be reduced, accompanied
by an elevation in [Ca2]i, most likely due to increased
oxidative stress (237).
All four PMCA isoforms are expressed in the human cor-
neal epithelium, and while PMCA4 is the predominant iso-
form, it appears that each isoform localizes to specific cell
layers, which perhaps reflects the different Ca2 require-
ments across the epithelium (369). Isoform-specific func-
tions in the cornea are largely unknown, although experi-
ments using siRNA to knockdown PMCA4 in cultured hu-
man corneal epithelial cells suggest an important role in
corneal wound healing (368).
Ca2 plays myriad roles in the retina, the area of the eye
that when hit by light begins the cascade of events which
results in stimulation of the optic nerve, from light trans-
duction in photoreceptors to subsequent neurotransmitter
release from these and retinal neurons, in addition to its
actions as a neuromodulatory intracellular second messen-
ger (8). The retina is composed of rod and cone photore-
ceptors (FIGURE 4C), with rod cells being of more abun-
dance and higher sensitivity and cone cells being responsible
for color vision. Early studies, in the tree shrew and sala-
mander, suggested PMCA was crucial in regulating intra-
cellular Ca2 concentration at these photoreceptor termi-
nals to allow the transmission of visual signals in the retina
by providing the main Ca2 extrusion pathway from inner
segments and synaptic terminals of photoreceptor cells
(194, 252) as highlighted in FIGURE 4D. PMCA2 has since
been identified to be heavily abundant in rod cells, but not
cone cells, where it forms a complex with other proteins
including membrane palmitoylated protein 4 (Mpp4)
(413). Further animal studies suggested this restricted ex-
pression of PMCA2 in rod cells is related to visual signaling
in this area of the eye.Mice lacking functional PMCA2 have
significantly impaired rod-mediated signaling, with the
level of light-evoked synaptic transmission being halved
compared with control animals, possibly related to the loss
of high-affinity Ca2 extrusion causing synaptic delays
(101). In addition, PMCA has been shown to regulate
[Ca2]i in rod bipolar cell synaptic terminals both at rest
and when stimulated, suggesting a role in adapting to back-
ground luminance (390). Finally, there has been a recent
report that PMCA1 expression is reduced in the retina of
diabetic retinopathy patients as well as fat-fed mice (69).
2. PMCA and the ear
The ear is one of the tissues in which we know most about
the physiological role of the PMCA,with the cardiovascular
system being the other area that has been widely studied, as
will be described below. It is PMCA isoform 2 that is of
great importance in hearing, with mutations in the protein
or its complete loss resulting in impaired hearing or even
deafness.
The inner and outer hair cells of the inner ear (FIGURE 5A)
have an essential role in converting sound waves, which
enter the cochlea, to electrical signals to be transmitted to
the brain. The tight regulation of intracellular Ca2 concen-
trations is governed by the mechanoelectrical transduction
channels which bring Ca2 into the cells and by PMCA2
which is involved in its extrusion (FIGURE 5B). PMCA2 is
expressed in specialized regions of the hair cells known as
stereocilia that are present in bundles at the apical end of the
cell from where they protrude into the endolymph; it is the
movement of the stereocilia caused by vibration of the en-
dolymph that leads to opening of the mechanoelectrical
transduction channels and subsequent Ca2 entry into the
cell (as reviewed in Ref. 135). By extruding Ca2 from the
stereocilia to the endolymph, PMCA2 has a dual role: 1) in
maintaining the low [Ca2]i concentration required within
the stereocilia and 2) in supplying essential Ca2 to the
endolymph which influences the mechanical response of
the stereocilia to vibrations (135). PMCA2 is localized to
the stereocilia of both the inner and outer hair cells, where
its expression progresses along the length of stereocilia in a
temporal manner. At birth its expression is localized just to
the base, then over a period of several days expression ex-
tends along the stereocilia all the way to the apex. This
changing pattern of expression mirrors the maturation of
the mechanoelectrical transduction channels (73). Using
immunogold labeling, Chen et al. (73) were also able to
determine that while PMCA2 was expressed on the inner
hair cells it was present at a considerably higher density in
all three layers of outer hair cells. PMCA2 is not the only
isoform to be expressed in the sensory hair cells; the ubiq-
uitously expressed PMCA1 is also expressed. It does how-
ever have a pattern of expression distinct from PMCA2 and
has been found to be localized to the basolateral plasma
membrane of the hair cells, suggesting specialized functions
for the two isoforms within the hair cell (99, 139).
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As has been described above, mutations in PMCA2 have
been linked to deafness and hearing loss in humans and in
genetically modified mice carrying a variety of PMCA2mu-
tations. Together this provides substantial support that
PMCA2 is crucial in maintaining tight control of the Ca2
concentrations required for the hair cells to perform their
essential role in the hearing process (38, 123, 336, 355, 365,
392).
3. PMCA and the olfactory system
Initiation of excitation in olfactory sensory neurons (OSN;
FIGURE 6A) occurs upon binding of odorants to G protein-
coupled receptors in the cilia, allowing Ca2 entry through
cAMP-gated channels and subsequent activation of Ca2-
activated Cl channels (238) (FIGURE 6B). Signal transduc-
tion occurs as the rise in [Ca2]i travels through the neuron
from dendritic knob to dendrite to cell body, and subse-
quent removal of Ca2 to basal levels terminates the signal
(321). The PMCAs, in addition to NCX and the ER Ca2
pump, are responsible for this Ca2 clearance, and all four
PMCA isoforms have been found to be expressed through-
out mouse OSNs with the exception of PMCA3 which is
absent from cilia and PMCA4 which has not been reported
in the dendrite (393). Treatment of isolated toadOSNswith
the PMCA inhibitor carboxyeosin significantly prolonged
relaxation of whole cell current in the cilia and slowed Ca2
clearance in mouse OSN knobs and cell bodies (62, 321).
Saidu et al. (321) found inhibition of PMCA, SERCA, and
NCX following OSN stimulation to each delay the rate
constant of Ca2 clearance by roughly 30%, suggesting a
similar contribution for each system. While the specific
function of each isoform has yet to be elucidated, OSNs
isolated from PMCA2 knockout mice exhibited signifi-
cantly impaired Ca2 clearance following stimulation to an
extent similar to total PMCA inhibition, suggesting a major
role for this isoform (321).
C. Role of PMCAs in the Central Nervous
System and Neurodegenerative Disease
Neuronal Ca2 signaling has many unique functions, being
critical to processes such as the regulation of synaptic trans-
mission in the control of neurotransmitter release, and the
formation and consolidation of memory (43). In addition,
Ca2 regulates processes common to other cell types such as
differentiation and cell death. In vitro studies in pheochro-
mocytoma cells have shown that knockdown of PMCA1
impairs neurite extension when stimulated with nerve
growth factor (40), as does antisense oligonucleotide treat-
ment of PMCA2 and 3 (362), suggesting a role for the
PMCA in neuronal differentiation. There is also evidence
for a role in the regulation of neuronal cell viability as
pheochromocytoma cell survival is respectively improved
or impaired by PMCA4 overexpression and knockdown
under conditions of Ca2 overload (131). Similarly, rat pri-
mary neurons and human SH-SY5Y neuroblastoma cells
transfected with PMCA2 siRNA display increased levels of
basal Ca2 and impaired Ca2 clearance following stimu-
lation, and increased cell death upon exposure to excito-
toxic concentrations of agents increasing [Ca2]i as well as
the glutamate receptor agonist N-methyl-D-aspartic acid
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(NMDA) (120). Furthermore, there is evidence that a num-
ber of neurotoxic agents cause proteolytic degradation of
the PMCA in rat cortical cultures, highlighting a potential
role in neurodegeneration caused by multiple etiologies
(146). Specifically, PMCA1 and 2 expressions have been
shown to be reduced in rat hippocampal pyramidal cells
following kainate-induced seizures (130), and PMCA4 and
2 each shows displacement from the plasma membrane and
internalization in rat hippocampal cells upon exposure to
toxic concentrations of glutamate in association with re-
duced Ca2 efflux (295). The following sections will further
explore the associations of the PMCA with specific neuro-
degenerative diseases.
1. PMCA and cerebellar disorders
The cerebellar cortex, composed principally of Purkinje
neurons, is the region of the brain predominantly involved
in motor control and sensory perception. The PMCA in
conjunction with NCX is responsible for precise control of
local Ca2 at excitatory parallel fiber-Purkinje neuron syn-
apse terminals, thus modulating neurotransmitter release
(316). Immunolocalization analysis of rat cerebellum sug-
gests that isoforms display specific patterns of expression,
with “neuronal” isoforms PMCA2 and 3 being predomi-
nately concentrated in post- and presynaptic terminals, re-
spectively (48). In contrast, the “ubiquitous” isoforms are
expressed at lower levels (47), where they may reside in
lipid rafts of cerebellar granule neurons in association with
NMDA receptors to regulate nitric oxide production (231).
As previously mentioned, two independent mutations in the
PMCA3 gene affecting calmodulin binding and Ca2 ejec-
tion, respectively, have been identified in patients present-
ing with cerebellar ataxia (50, 420); however, there is sub-
stantial evidence from PMCA2 mutant mice that this iso-
form is also critical to cerebellar function. PMCA2 is
strongly expressed in Purkinje cells, and both pharmacolog-
ical inhibition and genetic ablation of PMCA2 from Pur-
kinje neurons impair dendritic growth (109, 342). Further-
more, in addition to the aforementioned hearing loss,
PMCA2 null mutant mice display overt cerebellar ataxia
apparent 12 days after birth accompanied by a severe in-
ability to maintain balance and reduction in body weight
(192). Similarly, the wriggle mouse sagami strain, which
has a point mutation in the PMCA2 gene, displays involun-
tary dystonic movements of the extremities, writhing and
wriggling of the trunk and neck, and difficulty maintaining
an upright posture (166, 376). Mice with heterozygous in-
activation of the gene, however, appear outwardly normal
at rest, but experience abnormal coordination of the
hindlimbs upon exercise (111).
Studies in these transgenic mice have identified a number of
defects in cerebellar neuronal function and Ca2 homeosta-
sis. Cerebellar slices from wriggle mouse sagami for exam-
ple display a smaller rise in [Ca2]i and impaired clearance
following stimulation (376) in addition to a reduction in
synaptic connections between parallel fibers and Purkinje
dendritic spines (166). Purkinje neurons from PMCA2
knockouts meanwhile exhibit lower presynaptic Ca2 ex-
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trusion at these junctions, together with increased basal
Ca2 and impaired clearance, and increased firing of post-
synaptic inhibitory neurons which contributes to reduced
and irregular firing of action potentials in the Purkinje cells
(108–110). The phenotype of the PMCA2 knockout mouse
may be further exacerbated by the identification of a novel
association with the metabotropic glutamate receptor 1
(mGluR1), known to play essential roles in motor coordi-
nation, synaptic plasticity, and associative learning, which
is downregulated in the knockout cerebellum along with
subsequent downstream signaling (197). While the pheno-
type in heterozygous null mutants is less overt, there are
reports of impaired neuronal function in the Purkinje cells.
These include increased amplitude and slower recovery
times of Ca2 transients, reduced firing frequency of action
potentials, and loss of Purkinje cells by 20 wk of age (111,
115).
2. PMCAs in diseases of the spinal cord
There is a growing body of evidence to suggest that the
PMCA may play a protective role in preventing spinal cord
pathology. This may be highlighted by the finding that
PMCA1 and 3 are both downregulated in brain lesions
obtained from multiple sclerosis (MS) patients at autopsy
(217). Work in the rat using the experimental autoimmune
encephalomyelitis (EAE) model of MS, in which demyeli-
nation and subsequent ascending weakness and paralysis is
induced through immunization by myelin injection into the
foot, indicates a dramatic reduction in PMCA2 expression
in spinal cord neurons in a patternmirroring disease course,
which becomes restored during recovery (261, 262). A sim-
ilar downregulation of PMCA2 expression has also been
witnessed upon exposure of spinal cord neurons to the glu-
tamate receptor agonist kainate (198, 262).
Further evidence of a vital role for the PMCA in maintain-
ing Ca2 homeostasis and neuronal health in the spinal
cord has been detected upon pharmacological inhibition in
cultured rat spinal cord neurons. Kurnellas et al. (199)
found the pan-PMCA inhibitor carboxyeosin delayed Ca2
clearance with subsequent promotion of caspase activity
and neuronal death. The authors also found PMCA2
knockout and functionally inactive deafwaddler mice to
exhibit a significant loss of spinal cord motor neurons
(199), with further exploration revealing that PMCA2 si-
lencing in these cells reduced the expression of collapsing
response mediator protein 1 (CRMP1) before neuronal de-
generation (198). A recent study also suggests that PMCA2
and 3, in complex with NCX1 in lipid rafts, are critical for
the function of the neuronal glycine transporter 2 (GlyT2),
and hence regulating inhibitory glycinergic signaling, in
brain stem and spinal cord neurons, disturbances which are
known to be a major cause of the rare condition hyperek-
plexia (87).
3. PMCA and age-related neurological disorders
Advancing age often coincides with a progressive decline in
neuronal function, thought to be largely driven by the ac-
tions of reactive oxygen species (ROS). PMCA activity and
abundance declines substantially with age in synaptic
plasma membranes from rats, as does the extent of PMCA
activation by aged calmodulin (CaM) due to the oxidation
of CaM methionine residues (172, 240, 418). Likewise, a
range of oxidative agents have been shown to induce pro-
teolytic degradation and a reduction of PMCA activity in
rat synaptic membranes and cortical neurons (417, 419), as
well as causing PMCA internalization and loss of expres-
sion in primary hippocampal neurons (184). Given the crit-
ical importance of the PMCA in maintaining [Ca2]i, neu-
ronal function, and viability, it is therefore highly likely that
ROS-induced inactivation of the PMCA may contribute to
age-related neurodegeneration.
In addition to the aging brain, PMCA expression and activ-
ity have also been shown to be reduced in the cortex of
brains excised post mortem from patients with Alzheimer’s
disease (24, 25). Alzheimer’s disease is characterized by an
accumulation of amyloid -peptide (A) and tau protein,
and studies have found each of these to have an inhibitory
effect on PMCA activity in membrane vesicles from human
hippocampus and cerebral cortex, with A specifically af-
fecting the PMCA4 isoform (24, 25, 230). Recent data sug-
gest that PMCA activity may also be impaired in human
brain tissue from Parkinson’s disease patients (416), a dis-
ease characterized by loss of neurons in the substantia nigra
region of the midbrain leading to insufficient dopamine se-
cretion. This observation is supported by studies using the
Parkinsonian mimetic 1-methyl-4-phenylpyridinium
(MPP), which causes an increase in [Ca2]i and reduction
in PMCA2 expression in SH-SY5Y cells and rat primary
midbrain neurons (42). Interestingly Brendel et al. (42) also
demonstrated that transfection of PMCA2 siRNA reduced
neuronal viability while overexpression rendered cells resis-
tant to MPP-induced toxicity.
Overall, there is a substantial body of evidence to suggest
that multiple PMCA isoforms play a vital role in maintain-
ing neuronal viability and synaptic function through precise
regulation of Ca2 homeostasis and local signaling. It may
be that future therapies for excitotoxic and age-related neu-
rodegeneration may look to stabilizing or restoring PMCA
expression and function to prevent neuronal loss.
D. Role of PMCAs in the Cardiovascular
System
1. PMCA and the heart
It is now well established that Ca2 has a dual role in the
heart: 1) it is the driving force for myofilament contraction
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and relaxation, and 2) it has the ability to regulate the
intracellular signaling events, several of which dictate path-
ological cardiac remodeling associated with hypertrophy
and heart failure.
With the bulk of intracellular Ca2 being extruded from the
cytosol into the sarcoplasmic reticulum (SR) of the cardio-
myocyte by the SERCA and out of the cell via the NCX, the
PMCAs make only a minor contribution to Ca2 extrusion
during diastole and consequently have traditionally been
considered relatively insignificant in terms of normal Ca2
homeostasis in the heart (26, 77, 266, 405).
The presence of two isoforms (PMCA1 and PMCA4) sug-
gests specialized functions, and in recent years, through the
use of genetically modified mice, a role has emerged for
PMCA4 in the regulation of signal transduction processes.
In contrast, there is still little known of the role of PMCA1.
With its 10 transmembrane domains and large intracellular
loops, PMCA acts as a structural protein providing a scaf-
fold to anchor interacting proteins at the plasma mem-
brane. Within the heart, these interacting proteins include
nNOS and 1-syntrophinwhich interact with both PMCA4
and PMCA1, calcineurin A, and Ras-associated factor 1
(RASSF1) (13, 46, 335, 395). While the precise function is
not yet known of some of these interactions, others have
been well characterized to be of functional significance.
Of particular note in the cardiovascular system, the binding
of PMCA4 and nNOS at its PDZ domain has been shown to
influence basal contractility and -adrenergic responsive-
ness as well as, as will be discussed in the next section, to
have an influence on vascular tone (60, 61). This interaction
with nNOS was first identified in cultured cells, where
PMCA4 overexpression resulted in a reduction of nNOS
activity, postulated to occur due to the decreased availabil-
ity of local Ca2, while a mutant nNOSmolecule lacking its
PDZ domainwas unaffected (335). A functional interaction
was subsequently identified in the heart, where PMCA4
overexpression was found to attenuate the inotropic re-
sponse to -adrenergic stimulation to an extent comparable
to that seen following nNOS-specific inhibition in controls,
but not in mice overexpressing a mutant form of PMCA4
unable to interact with nNOS (266). This pathway has since
been characterized to affect local cGMP and hence cAMP
levels, thus modulating PKA activity at the SR (244, 245).
Interestingly, the latter of these studies found PMCA4
knockout mice to display a similar attenuation of the -ad-
renergic response, but have enhanced basal contractility
correlating with an increase in systolic Ca2 due to phos-
phorylation of the RyR at PKA-dependent serine residues.
Furthermore, the PMCA4-nNOS interaction may also have
disease implications following myocardial infarction, when
nNOS in association with its adaptor protein CAPON
(COOH-terminal PDZ ligand of NOS1), have been shown
to be recruited to the sarcolemma to bind to PMCA4 (22).
1-Syntrophin is a cytoskeletal protein which like nNOS
has a PDZ binding domain; however, although 1-syntro-
phin interacts directly with PMCA1 and PMCA4, it does so
by binding to a domain on the catalytic second intracellular
loop of PMCA. In the heart PMCA4 can form a ternary
complex with nNOS and 1-syntrophin which results in a
synergistic inhibition of nNOS-mediated NO production
(395).
RASSF1 also binds to the same domain on the second in-
tracellular loop of PMCA. A function of this interaction
became apparent when PMCA4 was overexpressed in cul-
turedHEK293 cells which resulted in the reduced activity of
RASSF1A, and inhibition of the activation of Ras-mediated
signaling (13). At the time RASSF1A, although a potential
upstream regulator of mitogen-activated protein kinase/ex-
tracellular signal-regulated kinase (MAPK/ERK) signaling,
was not known to be associated with the hypertrophic pro-
cess. However, RASSF1 knockout hearts have since been
shown to have an exacerbated response to pressure over-
load, through mediating ERK1/2 signaling (268). More re-
cently, it has been demonstrated that RASSF1 mediates the
TNF--induced contractile response and signaling in the
heart; however, it is not yet known whether these roles of
RASSF1 in the heart are directly influenced by its interac-
tion with PMCA4 (247, 268).
An association between the PMCA and calcineurin has been
witnessed in multiple isoforms in a number of cell types.
The interaction was first witnessed in PMCA4 overexpress-
ing HEK cells and mapped to the catalytic subunit of cal-
cineurin A, with consequential attenuation of calcineurin-
nuclear factor of activated T cells (NFAT) signaling (46).
Calcineurin has since been noted to also interact with
PMCA2 and 4 in breast cancer cells and PMCA1, 2, and 4
in endothelial cells (158, 159), as well as with PMCA4 in
the PC12 pheochromocytoma cell line (189). Calcineurin-
NFAT signaling is one of the best characterized pathways in
the development of pathological hypertrophy and remodel-
ing (248), and thus this has prompted research into the
function of this interaction during the hypertrophic process.
PMCA4 overexpression was found to significantly reduce
the extent and progression of pathological remodeling
through the attenuation of NFAT signaling (405), and in-
terestingly, we have recently found that deletion of PMCA4
also attenuates hypertrophic remodeling, through a cal-
cineurin-independent mechanism (242).
Using a number of mouse models in which PMCA4 was
deleted globally, or specifically from the cardiomyocytes or
from the fibroblasts, we demonstrated that PMCA4 is in-
volved in the development of pathological cardiac hyper-
trophy by regulating Ca2 signaling in cardiac fibroblasts
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which in turn is essential in the regulation of cardiac hyper-
trophy (242). Total PMCA4 knockout and deletion of
PMCA4 specifically from the fibroblasts protected the ani-
mals against pressure overload-induced cardiac hypertro-
phy, but this protection was not evident when PMCA4 was
deleted specifically from the cardiomyocytes. Ablation of
PMCA4 from cardiac fibroblasts led to an increase in
[Ca2]i which subsequently increased secreted frizzled re-
lated protein 2 (sFRP2) transcription, an inhibitor of the
Wnt signaling pathway known to be protective against in-
jury of the myocardium (151, 242). Secretion of sFRP2
from PMCA4 ablated fibroblasts then acted in a paracrine
fashion to reduce cardiomyocyte hypertrophy and confer
protection against the development of heart failure.
Cardiac hypertrophy almost invariably precedes the devel-
opment of heart failure, and as an important determinant of
disease progression and clinical outcome in heart failure
patients, cardiac hypertrophy presents a clear target for
disease prevention and treatment. With this in mind we set
out to identify a pharmacological inhibitor of PMCA4 to
use as an anti-hypertrophic agent. There is precedent that as
an ATPase the PMCA would make a suitable drug target in
that two of ourmost clinically successful drugs over the past
years have been the cardiovascular drug ouabain and the
antacid omeprazole, inhibitors of the Na-K-ATPase and
the H-K-ATPase, respectively. The ease with which the
inhibition of the ATPase activity of PMCA4 (and other
ATPases) can be measured lends itself to drug screening and
led to the identification of aurintricarboxylic acid (ATA) as
a potent inhibitor of PMCA4 (58, 241, 243, 246). ATAwas
found to inhibit PMCA4 at low concentrations (having an
IC50 of 150 nM) and to have minimal effect on PMCA1, the
other isoform of PMCA present in the heart (241). This
novel and potent inhibitor of PMCA4was successfully used
to both prevent the development of pathological cardiac
hypertrophy in an in vivo mouse model, and of greater
potential clinical relevance it was shown to have the ability
to reverse established cardiac hypertrophy in the mouse
(242). To add further weight to the notion of essaying
PMCA4 inhibition as an anti-hypertrophic therapy, it has
recently been shown that crossing PMCA4 null mice with
mice expressing a mutant form of -tropomyosin prevents
the development of spontaneous hypertrophic cardiomyop-
athy which would otherwise occur (297).
2. PMCA and the vasculature
In addition to its regulatory roles in contractile and hyper-
trophic processes in the heart, several roles have been iden-
tified for the PMCA in noncardiac cell types in the cardio-
vascular system (59). In contrast to cardiac muscle, it has
been demonstrated that the PMCA accounts for the bulk of
Ca2 extrusion from vascular smooth muscle, and its inhi-
bition prolongs aortic relaxation to a similar extent to that
of SERCA while NCX inhibition has little effect (298), and
in myometrial resistance arteries PMCA inhibition mimics
the phenotype of preeclamptic vessels (398). As described in
section IIIA, PMCA1 has been identified in numerous stud-
ies as a leading candidate gene for the development of hy-
pertension. It is perhaps not surprising therefore that both
PMCA1 and 4 have been shown to influence vascular tone
(129, 141, 187, 333, 343) and that they have been identified
as potential targets for the treatment of essential hyperten-
sion (214).
Both PMCA1 and PMCA4 have been identified in vascular
smooth muscle cells from a variety of species including
mouse, rat, and pig (4, 187, 269, 276, 326, 363). Both have
also been identified in endothelial cells (276, 363). Adding
extra weight to the potential significance of the expression
of the PMCAs in the vasculature is the fact that functional
interactions between PMCA1 and 4 and eNOS, the major
producer of the vasodilator NO in the vasculature, have
been identified in endothelial cells (158). However, it is
again through the study of a number of mouse models car-
rying genetic mutations in either PMCA1 or PMCA4 that
we have gained our understanding of the role of these genes
in the regulation of vascular tone and blood pressure.
There is an accumulation of evidence that PMCA1 is im-
portant in arterial contractility and blood pressure regula-
tion and that modified expression results in hypertension.
Three different mouse models, all of which exhibit reduced
expression of PMCA1, develop raised blood pressure. Hy-
pertension in a model in which PMCA1 was specifically
deleted from the vascular smooth muscle cells was found to
correlate with increased intracellular Ca2 (187), global
heterozygous deletion of PMCA1 also resulted in raised
blood pressure (129), and PMCA1 knockdown by siRNA
led to an elevation in blood pressure (343) associated with
structural changes to the walls of the resistance arteries.
Although to date there is no GWAS data linking PMCA4
with hypertension, there is evidence from mouse models
that it is important in the regulation of vascular tone and
blood pressure. Mice overexpressing PMCA4 in smooth
muscle cells have been shown to have elevated blood pres-
sure (141, 333). While this may appear counterintuitive as
increased expression of a Ca2 extrusion pump would po-
tentially lead to lower intracellular Ca2 levels and subse-
quent vascular relaxation, it is in fact through the negative
regulation of nNOS that PMCA4 acts to regulate vascular
contractility (141, 333).
E. Role of PMCAs in Hematopoietic Cells
With PMCA first discovered and isolated in human eryth-
rocytes (327), numerous studies have looked at the role of
the pump in hematopoetic cells. Perhaps more than any
other cell population, the PMCA is the predominant Ca2
extrusion system in blood cells (erythrocytes, leukocytes,
and platelets) where maintenance of intracellular Ca2 lev-
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els is essential for the regulation of cellular function, signal-
ing, metabolism, and blood rheology (33, 211, 313). Vari-
ations in PMCA activity can impact Ca2 homeostasis in
blood cells and have been associated with numerous aspects
of health and disease, as we will highlight below.
1. PMCA in erythrocytes
Aside from some internal buffering capacity, the PMCA is
the sole mechanism responsible for the maintenance of free
cytosolic [Ca2] in erythrocytes (122, 210). Coupled with
the relative ease with which patient samples can be ob-
tained, this has made red blood cells and red blood cell
ghosts (erythrocytes which do not contain hemoglobin or
other cytoplasmic components but retain their shape) a
popular choice in which to study the biochemical properties
of human PMCA. Using these models, researchers have
been able to identify abnormalities in PMCA activity in a
number of disease states (28, 291). In addition, purified
preparations of human erythrocyte PMCA have been
widely used to identify molecular and pharmacological
modulators of the pumps’ activity such as F- and G-actin,
acidic phospholipids, diacylglycerol, the bidentate chro-
mium (III) ATP complex, the phytoalexin resveratrol, and
inhibitory peptide caloxin1c2 (251, 263, 277, 278, 289,
383).
In erythrocytes, Ca2 regulates numerous parameters such
as cell volume and rheological properties, metabolic activ-
ity, redox state, and cell clearance (33). Human erythrocyte
PMCA is composed primarily of PMCA4, with PMCA1
expression also having been identified (188, 352). PMCA
activity declines as red blood cells age in line with increasing
glycated hemoglobin, which may make them prone to Ca2
overload and earmark them for clearance (207).
Elevated [Ca2]i is a feature of a number of diseases of the
erythrocyte associated with hemolytic anemia such as sickle
cell disease (SCD), -thalassaemia, and familial phospho-
fructokinase (PFK) deficiency (103, 315, 340). In SCD- and
PFK-deficient cells, Ca2 accumulates via increased entry
through the red cell membrane, in a stochastic fashion in the
case of sickled cells (209), likely causing a reduction in
deformability (the ability for cells to change shape in re-
sponse to flow) and leaving them prone to hemolysis (114,
315). Interestingly, in SCD a reduction in PMCA activity is
likely to contribute to this Ca2 accumulation (114),
whereas in PFK deficiency a compensatory increase in
PMCA activity to clear the Ca2 leads to ATP depletion
(315). There is also a suggestion that in an effort to prevent
Ca2 overload, both SCD and -thalassaemia erythrocytes
are able to store Ca2 in endocytic inside-out vesicles,
pumping it in via the PMCA (35, 208).
Hypertension is also associated with a decrease in red blood
cell deformability, where it may contribute to an increased
risk of vascular occlusion (78, 249). PMCA activity is re-
duced in erythrocytes from hypertensive patients and ap-
pears directly correlated with erythrocyte deformability.
Studies suggest deformability reduces by 55% upon PMCA
inhibition and increases upon PMCA activation with neu-
tral or acidic phospholipids (249). Similarly, a 50% reduc-
tion in erythrocyte PMCA activity has been reported in
women suffering from preeclampsia (259), and this has
been ascribed to changes in lipid composition, specifically
an increase in the level of lipid peroxidation (273).
2. PMCA in leukocytes
Ca2 signaling in leukocytes is required for processes such
as lymphocyte activation, granule secretion in granulocytes,
and the regulation of cell motility and death (211, 328). The
presence of a PMCA, thought to be predominately isoform
4, has been demonstrated in all classes of lymphocytes, as
well as neutrophils, monocytes, macrophages, and mast
cells (67, 132, 177, 211, 329, 338).
The PMCA represents the major route for Ca2 clearance
from human T cells, where it regulates [Ca2]i in conjunc-
tion with the main Ca2 entry channels, calcium release-
activated channels (CRAC, encoded by ORAI) (211). To
facilitate T-cell activation, there is a redistribution of the
PMCA to maximize Ca2 entry through CRAC (299), and
decreased PMCA-mediated efflux through an interaction
with stromal interacting molecule-1 (STIM1) (314) which
together increase cytosolic Ca2 thus activating NFAT. In
contrast, defective PMCA signaling, for example through
decreased expression following exposure to ROS, can pro-
mote T-cell apoptosis (286). There is also evidence that
through an interaction with CD147, PMCA4 is able to
modulate the immune response in T cells by inhibiting the
production of interleukin-2 (361). A rise in Ca2 in B-lym-
phocytes meanwhile is important for their proliferation,
differentiation, and antibody production, and studies have
shown that through positive and negative PMCA regula-
tion, respectively, CD22 and myc transcription factors are
able to either inhibit or stimulate these processes (71, 144).
PMCA activity has also been shown to be altered in disease
states in neutrophils. Both hepatocytes and neutrophils
from patients with alcoholic liver disease exhibit elevated
basal Ca2 and impaired PMCA-mediated efflux (16),
while the ability of PMCA inhibition to attenuate neutro-
phil apoptosis is lost in patients with uremia (80).
3. PMCA in platelets
Tight regulation of platelet Ca2 homeostasis is essential
for maintaining low resting Ca2 levels and also allowing
steep rises to enable platelet activation, platelet aggrega-
tion, and thrombus formation at sites of injury; underactive
platelets are associated with bleeding disorders, while hy-
peractivation can result in thromboembolism (88, 313). As
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is the case in erythrocytes and leukocytes, the PMCA is the
major Ca2 extrusion system in platelets (318), with ex-
pression studies showing PMCA4 to be the predominant
isoform (281). Studies have found that PMCA4 is recruited
to the cytoskeleton during platelet activation through an
interaction with the LIM family protein CLP36 to facilitate
clot formation (39). The critical role of the PMCA during
aggregation has been highlighted by studies using platelets
from PMCA4 knockout mice, which display impaired
platelet aggregation when stimulated with collagen (174).
Similar results were obtained upon incubation of platelets
with the PMCA inhibitor carboxyeosin, which led to ele-
vated resting Ca2, but smaller increases in Ca2 upon
stimulation alongside reduced aggregation (174).
Altered platelet PMCA activity has been witnessed in a
number of disease states associated with an increased risk of
clot formation or bleeding. As we will discuss in the follow-
ing section, platelet PMCA4 expression is elevated during
diabetes, but this is accompanied by an overall reduction in
PMCA activity in type 2 diabetic platelets as a result of
increased tyrosine phosphorylation (66, 168, 317). A simi-
lar reduction in PMCA activity has been reported in plate-
lets from hypertensive patients in a manner that correlates
with increasing diastolic blood pressure, again despite in-
creased expression of PMCA4 (82, 89). As in diabetes, this
occurs as a result of tyrosine phosphorylation, leaving
platelets with elevated [Ca2]i and in a potentially hyperac-
tivated state prone to spontaneous aggregation and throm-
bus formation (30). Increased PMCA4 expression has also
been reported in a family with type 2B von Willebrand
disease, where it is associated with the production of imma-
ture megakaryocytes and severe thrombocytopenia (265),
while increased PMCA activity has been found in platelets
from obese patients associated with increased anisotropy
(302).
F. Role of PMCAs in Pancreatic -Cell
Function and Diabetes
An increase in cytosolic Ca2 is required to stimulate insu-
lin release from pancreatic -cells in response to a rise in
glucose (401), and as such, disturbances in the regulation of
[Ca2]i can have profound effects upon -cell function and
may be a potential mechanism leading to the development
of type 2 diabetes. In addition, Ca2 signaling is important
in regulating -cell mass, apoptosis, and proliferation, key
events in the cytokine and nutrient-induced destruction of
pancreatic islets which occur in type 1 and type 2 diabetes,
respectively (79, 154).
Ca2 clearance from pancreatic -cells is regulated by the
SERCA, NCX and PMCA, with relative contributions esti-
mated to occur at around a 2:1:1 ratio among these three
systems in mice (72). Surprisingly for nonneuronal cells, all
four PMCA isoforms are expressed at the mRNA and pro-
tein level in rat islets, including up to eight splice variants
(175), suggesting highly specialized functions. Unusually,
the “neuronal” isoforms PMCA2 and 3 may have particu-
lar importance in -cells as their expression is downregu-
lated upon exposure of insulin-producing RINm5F cells to
the inflammatory cytokine interleukin-1, thought to be a
major cause of autoimmune death in type 1 diabetes (349).
In addition, glucose has been shown to decrease PMCA
activity, suggesting a possible link to altered -cell function
in type 2 diabetes (153).
Gain- and loss-of-function studies have shown that altered
expression of either NCX1 or PMCA2 is sufficient to mod-
ulate insulin secretion, -cell mass, proliferation, and sur-
vival (155). PMCA2 overexpression in insulin-secreting
BRIN-BD11 cells leads to reduced increases in intracellular
Ca2 in response to depolarization and glucose accompa-
nied by increased glucose metabolism and insulin secretion
(176), while depleting cytosolic, mitochondrial, and ER
[Ca2] and triggering apoptosis via the mitochondrial path-
way (171). In contrast, pancreatic islet cells isolated from
mice with heterozygous PMCA2 deletion were found to
display increased Ca2 stores and glucose-induced insulin
release, along with having higher rates of -cell prolifera-
tion with greater mass, viability, and islet size (275).
Diabetes is of course a major risk factor for the develop-
ment of various diseases, and PMCA activity has been
found to be altered in numerous nonpancreatic cell types
both clinically and in experimental models of diabetes. A
number of studies have found abnormal PMCA function in
hematopoietic, vascular smooth muscle, or endothelial cells
which may contribute to the increased risk of cardiovascu-
lar complications such as thrombus formation and athero-
sclerosis in diabetic patients.
An examination of Ca2 clearance proteins in platelets
from diabetic patients has shown PMCA4 expression to be
increased in both insulin-dependent and -independent dia-
betes, and this can be corrected upon insulin treatment in
type 1 diabetics (66). In line with the increased expression,
platelets from insulin-dependent diabetic patients have pre-
viously been found to have higher PMCA activity (234),
while incubation of platelets from healthy donors with low-
density lipoprotein (LDL) isolated from type 1 diabetic pa-
tients also increased PMCA activity along with resting
[Ca2] and platelet aggregation responses (300). On the
contrary, PMCA activity appears to be reduced in platelets
from type 2 diabetic patients likely due to increased tyrosine
phosphorylation as a result of oxidative stress (168, 317),
as well as in lymphocytes which may contribute to higher
basal [Ca2] in these cells (19).
Similar to the situation seen in platelets, human aortic en-
dothelial cells incubated with type 1 diabetic patient LDL
were found to have increased basal [Ca2]i and higher
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PMCA activity, along with alterations in the plasma mem-
brane structure which could lead to an atherogenic pheno-
type (301). Meanwhile, coronary smooth muscle cells iso-
lated from swine following induction of diabetic dyslipide-
mia have been found to have increased basal [Ca2]i due to
reduced PMCA-mediated efflux, a phenomenon which can
be prevented through exercise training (399, 400).
Altered PMCA activity may also lead to disturbances in
Ca2 homeostasis in other cell types during diabetes. For
example, basolateral membrane vesicles isolated from syn-
cytiotrophoblast of insulin-dependent diabetic patients dis-
play increased PMCA activity (359), while reduced PMCA
activity or expression has been identified in parotid and
submandibular salivary glands, kidney, and brain synapto-
somes of streptozotocin-induced diabetic rats (260, 347,
421).
G. Role of PMCAs in Visceral Smooth
Muscle
Smooth muscle contraction is triggered by the influx of
extracellular Ca2 following membrane depolarization
through Ca2 channels at the sarcolemma, or via IP3-medi-
ated SR Ca2 release following agonist-induced activation
of G protein-coupled receptors. Through its binding of cal-
modulin, the rise in cytosolic Ca2 activates myosin light
chain kinase (MLCK) leading to phosphorylation of the
myosin light chain (MLC), thus increasing actin-myosin
crossbridge formation and stimulating contraction. Relax-
ation is brought about by a decrease in cytosolic Ca2 via
SERCA-mediated SR reuptake and sarcolemmal extrusion
through the PMCA and NCX, with inactivation of MLCK
and activation of MLC phosphatase leading to the dephos-
phorylation of the MLC. The physiological role of the
PMCA in this process in visceral smooth muscle will be
discussed below.
1. PMCA in uterine smooth muscle
The contractile state and function of the myometrium influ-
ences reproductive processes such as implantation and par-
turition and can contribute to a number of disease states
including spontaneous miscarriage, preterm labor, dysmen-
orrhea, and endometriosis (5).
Experiments in rat uterine smooth muscle cells have deter-
mined that Ca2 extrusion at the plasma membrane is re-
quired for full recovery of transients induced by both mem-
brane depolarization and Ca2 release from internal stores
(345). In the nonpregnant myometrium, it is believed that
the PMCA is responsible for producing ~85% of relaxation
and 70% of Ca2 extrusion, while work in PMCA4 ablated
mice has identified that ~80% of the PMCA contribution
can be attributed to this isoform (233). In the endometrium
however, PMCA1 appears to be the dominant isoform, and
its expression has been found to increase along with TRPV6
during the proliferative phase of the menstrual cycle (412).
In contrast to nonpregnant myometrium, it has been sug-
gested that up to 70% of Ca2 efflux occurs via the NCX in
the pregnant rat uterus (344). This switch in mode of Ca2
extrusionmay be explained by an examination of the effects
of physiological concentrations of oxytocin on humanmyo-
metrium taken at term, which found the hormone to
strongly inhibit Ca2-ATPase activity and thus induce con-
traction (294), a phenomenon which has also been recipro-
cated at late stages of gestation in the rat (222). Surpris-
ingly, oxytocin’s inhibitory actions on PMCA and SERCA
activity at term occur despite an increase in expression of
both pumps in the human myometrium during active labor
(374).
2. PMCA in bladder smooth muscle
Tight regulation of [Ca2]i in detrusor smooth muscle of
the urinary bladder is critical to allow for relaxation while
filling and storing urine, and contraction during micturi-
tion. Disturbances in these processes can lead to lower uri-
nary tract symptoms such as urgency, frequency, and incon-
tinence, which primarily manifest themselves with increas-
ing age (10). Indeed, studies in guinea pig smooth muscle
have found Ca2 extrusion to be impaired in aged animals
as a result of decreased PMCA activity (138).
With the use of inhibitors to SERCA and NCX in PMCA
gene-ablatedmice, the relative contribution of the PMCA to
relaxation of bladder smooth muscle rings was estimated to
be ~25–30%, slightly greater than that of SERCA and with
the NCX responsible for up to 70% of relaxation (216).
This is largely compatible with data from isolated guinea
pig detrusor smooth muscle cells which, using inhibitors to
each system, estimated the relative contributions of PMCA,
NCX, and SERCA to Ca2 clearance to be 27, 55, and
31%, respectively (138). Interestingly, Liu et al. (216) also
found PMCAablation to impair the rate of contraction, and
in a further study in which contraction and [Ca2]i were
measured simultaneously, it was determined that the loss of
PMCA4 significantly inhibited the force and rate of con-
traction, as well as the rates of increase and decrease of
[Ca2]i following cholinergic stimulation (215). In con-
trast, the authors found heterozygous PMCA1 deletion to
elicit larger increases in [Ca2]i and rate and force of con-
traction following KCl stimulation, suggesting a greater
role for this isoform in overall Ca2 extrusion.
H. Role of PMCAs in Epithelial Ca2
Absorption and Tissue Mineralization
Regulated Ca2 absorption is critical in maintaining serum
[Ca2] at desirable levels for a wide range of normal phys-
iological functions, in addition to the mineralization of cal-
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cified tissues such as bone and enamel. In mammals, the
bulk of Ca2 transport occurs in the small intestine and
kidney, either paracellularly directly from the lumen to the
extracellular space via tight junctions, or transcellularly
through epithelial cells (157) (FIGURE 7). The PMCA, along
with NCX1, performs the final step in transcellular Ca2
absorption, extruding Ca2 from the epithelia to the inter-
stitial space at the basolateral membrane following its entry
from the lumen via TRPV5/6 channels and subsequent dif-
fusion through the cytosol bound to calbindin. The impor-
tance of PMCA1, the major isoform in epithelial absorp-
tion, in maintenance of serum ionic balance can be high-
lighted by the genome-wide association of the SNP
rs7965584 in the region of ATP2B1with serumMg2 con-
centration (239). This section discusses the role of the
PMCA in intestinal and renal Ca2 absorption, how it is
affected by disease states, and the implications this can have
on skeletal and dental mineralization.
1. PMCA and intestinal Ca2 absorption
In the intestine, the majority of transcellular Ca2 absorp-
tion occurs in the duodenum (181), where it is primarily
extruded from enterocytes via the PMCA (95). In addition,
it has been demonstrated that the PMCA plays an active
role in Ca2 transport in the large bowel, with basolateral
membrane vesicles isolated from human colon able to up-
take Ca2 in aMg2/ATP-dependent calmodulin-regulated
manner (323).
Expression studies have shown that PMCA1 is the predom-
inant isoform in both human and rat duodenal mucosa, and
therefore, this isoform is likely to be largely responsible for
Ca2 absorption in the intestine (163). Indeed, PMCA1
expression levels positively correlate with both intestinal
Ca2 absorption and bone mineral density in mice (11,
308). In rabbit and mouse small intestine it has been shown
that PMCA1 expression is higher proximally in the duode-
num than in the jejunum or ileum, and in the large bowel
higher in the cecum and ascending colon than in the de-
scending colon (9, 125). Alexander et al. (9) also found that
PMCA1 was the only isoform present in enterocytes
throughout human and mouse intestine, whereas PMCA4
was the predominant isoform in smooth muscle layers, in-
creasing in expression distally from small to large bowel.
As with most components of the transcellular pathway for
Ca2 absorption, duodenal PMCA1 expression is primarily
regulated by the vitamin D metabolite 1,25-(OH)2D3. Data
from rat intestine indicate that PMCA1 expression de-
creases substantially in aged animals in line with serum
1,25-(OH)2D3 concentration (12). Treatment of human du-
odenal mucosal explants with 1,25-(OH)2D3, as well as its
in vivo administration in mice and chickens, has been
shown to significantly increase PMCA1 expression (20, 49,
202, 388). Along with the upregulation of TRPV6 and cal-
bindin-D9K, this enables the gut to increase Ca
2 absorp-
tion in an attempt to maintain Ca2 balance under experi-
mental conditions of dietary Ca2 deficiency, as well as a
dietary depletion or excess of phosphorus and chronic met-
abolic acidosis (49, 65, 70, 179).
There is also evidence for a role in the regulation of duode-
nal PMCA1 expression by estrogens, with ovariectomized
rats andmice displaying reduced PMCA1mRNA (97, 379).
This experimental model results in negative Ca2 balance
and displays many characteristic features of postmeno-
pausal osteoporosis. In support of this role, intestinal
PMCA1 expression is increased in pregnant and lactating
mice, and in response to 17-estradiol treatment in ovari-
ectomized rats (378, 379).
The potential link between aberrant duodenal PMCA1 ex-
pression and inadequate bone mineralization can also be
highlighted by recent data showing enterocyte-specific
PMCA1 deletion in mice to lead to growth restriction and
reduced bone mineral density (320). Furthermore, intesti-
nal PMCA1 expression was found to be downregulated in
ulcerative colitis patients and in mice fed on a high-fat diet,
the latter finding also correlatingwith reduced bonemineral
density (402, 409), and both inflammatory bowel disease
and obese patients have a higher risk for the development of
NCX
PMCA1
TRPV
Epithelial cell
Endothelial cell
Gut/DCT
lumen
Interstitial
space
Blood vessel
lumen
3 Na+
Ca2+ Paracellular
Transcellular
Calbindin
FIGURE 7. Cartoon illustrating transepi-
thelial Ca2 absorption into the blood.
Ca2 moves passively from gut/kidney lu-
men through tight junctions between epi-
thelial cells to the interstitial space (para-
cellular) or is actively transported across
the epithelial cell (transcellular). Ca2 en-
ters the cell via transient receptor potential
vanilloid channels, is transported across
the cytoplasm bound to calbindins, and ex-
its via the NCX and PMCA1 to the intersti-
tial space.
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bone-related disorders including osteoporosis (140, 150).
In addition, duodenal PMCA1 levels are lower in pregnant
hypoxic rats than normoxic controls which may contribute
towards growth restriction in preeclamptic offspring (411).
2. PMCA and renal Ca2 reabsorption
In excess of 98% of the Ca2 filtered through the glomeruli
is reabsorbed into the plasma along the nephron. Approxi-
mately two-thirds of this transport occurs passively in the
proximal convoluted tubule, 20% in the thick ascending
loop of Henle, and 10 and 5% in the distal convoluted
tubule (DCT) and connecting tubule, respectively, the main
sites for active Ca2 absorption (127, 157). Unlike in the
intestine, it is NCX1 that is believed to reabsorb the major-
ity of transcellular Ca2 at the basolateral membrane, with
the PMCA responsible for the remaining one-third (29).
The presence of aMg2-dependent Ca2-ATPase was dem-
onstrated throughout the rabbit nephron in the early 1980s,
with activity highest in the DCT and cortical collecting
tubule (98). Since then, mRNA for all four PMCA isoforms
has been found with site-specific distribution along the
nephron. Interestingly, PMCA3 expression appears to be
restricted mainly to the thin descending loop of Henle in the
rat nephron, whereas isoforms 1, 2, and 4 show more gen-
eral distribution along the nephron (53, 55). PMCA1 and 4
predominate in mouse DCT cells where they appear tar-
geted to the basolateral membrane (223), and immunohis-
tochemical staining of the mouse nephron shows PMCA
expression to peak in the late DCT and connecting tubule
where transcellular Ca2 transport occurs, before expres-
sion tapers off towards the collecting duct (218).
In contrast to intestinal absorption, recent data suggest that
PMCA4 may be the major isoform involved in renal active
Ca2 transport, where it shows strong localization to distal
tubular regions in human and mouse kidney (9). In a cul-
tured murine model of the distal convolution, PMCA4, but
not PMCA1, was found to be enriched when compared
with total cortical expression along with the other compo-
nents of renal transcellular transport TRPV5, calbindin-
D28k, and NCX1 (381). Given this evidence regarding the
expression of PMCA4 it was then interesting to note that in
vivo deletion of PMCA4 from the mouse does not affect
renal Ca2 handling, with the mice displaying normal se-
rum Ca2 levels and urinary Ca2 excretion (242, 382). As
is the case in the digestive tract, active Ca2 transport is
primarily regulated via 1,25-(OH)2D3 in the distal tubule,
and it has been shown that vitamin D3 treatment of Madin-
Darby canine kidney cells leads to significant upregulation
of basolateral PMCA4 expression in line with an increase in
apical-to-basolateral membrane Ca2 flux (185).
Interestingly, the pathways regulating PMCA expression in
the renal cortex appear to show isoform specificity; whereas
PMCA4 expression is induced by 1,25-(OH)2D3, and
PMCA1 expression is dramatically reduced in the kidney of
ovariectomized rats and estrogen-deficient aromatase
knockout mice (97, 274). In contrast, a low phosphate diet
induces PMCA2 and 3 downregulation and a correspond-
ing increase in urinary Ca2, while PMCA1 expression is
unaltered by dietary Ca2 levels (54, 97).
Associations have been identified between abnormal
PMCA activity and a number of disease states involving the
kidney. Patients with idiopathic hypercalciuria, an inher-
ited condition associated with an increased risk of kidney
stones, display significantly higher erythrocyte PMCA ac-
tivity than healthy controls (28). In contrast, red blood cell
PMCA activity is reduced in line with an increase in cyto-
solic Ca2 in both children and adults with chronic kidney
disease (CKD) (253, 293). In children, erythrocyte PMCA
activity and Ca2 balance deteriorates as CKD progresses
and can be only partially and transiently rescued by hemo-
dialysis (291, 292). There is also evidence from the rat that
gestational diabetes induced by streptozotocin (STZ) can
impact on PMCA expression and urinary Ca2 output in
neonatal male offspring which persists into adulthood (34),
while STZ-induced diabetes in the adult rat reduces renal
PMCA1 expression and increases urinary Ca2 excretion
(421). In both these cases, the disturbance in Ca2 balance
ultimately leads to reduced trabecular bone formation, a
likely mechanism contributing towards the development of
diabetes-induced osteoporosis.
3. PMCA and bone mineralization
As detailed in the previous sections, it is clear that pertur-
bations in duodenal and renal PMCA expression may im-
pact on bone mineral density (12, 34, 320, 409, 421). Fur-
thermore, altered maternal PMCA expression also appears
to influence bone formation in offspring. This is evident
both in the placenta, where PMCA3 levels correlate
strongly with neonatal bone area and mineral content
(232), as well as during lactation where a decrease in
PMCA2 expression in mammary epithelial cells from 1,25-
(OH)2D3-deficient dams is associated with reduced cortical
bone volume in pups (170). In fact, PMCA1, 2, and 4
mRNA and total PMCA protein each increases dramati-
cally during lactation in rat mammary tissue, most notably
that of PMCA2 which is upregulated some 1,500- and 100-
fold at the RNA and protein levels, respectively (303, 304).
The importance of this increase in PMCA2 expression in
transport of Ca2 from mammary epithelial cells into milk
has since been verified through studies in transgenic mice,
which show a 60–70% reduction in milk [Ca2] produced
by PMCA2 null or functionally inactive Deafwaddler mice
(306, 385).
In addition to serum and milk [Ca2], the degree of bone
mineralization depends on optimal Ca2 homeostasis
within the bone forming and resorbing cell types of the
tissue itself, namely, the osteoblasts and osteoclasts. Bone is
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a highly dynamic tissue that undergoes constant turnover.
Osteoblasts lay down new osteoid through matrix, Ca2,
and phosphate secretion, forming a specialized connective
tissue hardened by hydroxyapatite. Meanwhile, osteoclasts
simultaneously digest this osteoid, and the balance of these
two processes impacts on bone growth and strength (84).
PMCAs are expressed in both cell types, although their
precise functions are incompletely understood. PMCA1, 2,
and 4 have all been found to be present in human osteo-
blasts (41, 196, 380). In human and rat osteoblasts, the
PMCA appears targeted to the osteoidal domain, suggest-
ing a role in the mineralization process (258, 380), although
chick osteoblasts show localization to the apical and lateral
membranes facing away from bone so there may be some
interspecies variation in this respect (7, 351). In support of
a role in basolateral Ca2 transport, PMCA inhibition us-
ing ortho-vanadate has been shown to decrease mineraliza-
tion of murine osteoblast precursor cultures (257), while
patients suffering from adult idiopathic scoliosis appear to
have a reduction in PMCA4 expression (41).
It has been reported that PMCA1 and 4 are expressed dur-
ing osteoclast differentiation from human peripheral blood
mononuclear cells, and each acts to inhibit osteoclastogen-
esis through regulation of Ca2 oscillations, NFATc1, and
in the case of PMCA4, NO-dependent osteoclast fusion
(183). In mature human, mouse, and chick osteoclasts, the
PMCA appears localized to the basolateral membrane fac-
ing away from bone (7, 183, 380). In addition to PMCA’s
role during osteoclastogenesis, they also appear to prevent
apoptosis in mature cells, while both PMCA1 heterozygous
mice and PMCA4 ablated mice exhibit reduced bone min-
eral density and trabecular bone volume associated with
increased osteoclast number (183). Interestingly, this study
also found a correlation between PMCA4 expression and
higher peak bone mass in Chinese women.
4. PMCA and dental mineralization
Enamel is the hardest substance in the human body, being
composed primarily of calcium phosphate in the form of
hydroxyapatite. It is laid down during tooth development
by ameloblasts, and constantly remineralized thereafter via
Ca2 and phosphate secreted in saliva (161).
PMCA has been shown to be localized to the enamel facing
Tomes’ processes and plasma membrane of human amelo-
blasts, indicating a likely role in enamel mineralization, and
indeed PMCA1 and 4 expressions have been shown to in-
crease in parallel with the onset and progression of enamel
development (37). The importance of PMCA1 in the min-
eralization process may be highlighted by work using mor-
pholino knockdown of the zebrafish Atp2b1a gene, which
leads to inadequate calcification of developing pharyngeal
teeth (136), while PMCA4 expression is reduced in matrix
metalloproteinase-20 (MMP20) null mice in which enamel
thickness is reduced by 50% (375).
Regulation of salivary Ca2 levels is critical in preventing
the incidence of dental caries and formation of calculus, and
the PMCA is the principal route via which Ca2 is extruded
from acini into the salivary ducts. PMCA1, 2, and 4 are
each expressed in the human parotid and submandibular
glands, where they appear localized to the apical membrane
of acinar cells (161). PMCA2 was also found to be present
in the secretory canaliculi between the cells, while labeling
of all three isoforms was found in the cytoplasm of the
interlobular and intralobular ducts of rabbit submandibu-
lar glands (36).
I. Role of PMCAs in Cell Proliferation,
Differentiation, and Death
Ca2 is known to be a widespread intracellular messenger,
controlling numerous cellular processes from cell growth to
cell death. When the level of cytosolic Ca2 changes, a
multitude of downstream signaling pathways driving these
processes become activated and therefore the regulation of
intracellular Ca2 is a key element of cellular physiology
(23). With the PMCA being the major regulator of [Ca2]i
in many cell types, it therefore plays a critical role in direct-
ing Ca2-mediated signaling, and as discussed elsewhere in
this review can influence such processes as megakaryocyte,
osteoclast, and neuronal differentiation (40, 41, 66, 82,
183, 362); the proliferation of B-lymphocytes and pancre-
atic -cells (71, 144, 275); and apoptosis of -cells, oste-
oclasts, and neurons (120, 131, 171, 183). Indeed, microar-
ray analysis of PC12 cells following antisense-mediated
suppression of PMCA2 or PMCA3 revealed altered expres-
sion patterns of many genes involved in the regulation of
cell cycle, proliferation, migration, differentiation, and ap-
optosis (31). Furthermore, cellular proliferation, differenti-
ation, and survival are key determinants in tumor progres-
sion which we will discuss in further detail in section IVJ.
1. PMCA during differentiation
Direct evidence that the PMCA may play a role in regulat-
ing the differentiation process has been demonstrated upon
overexpression of human PMCA4 in rat L6 myoblasts,
which led to reduced [Ca2]i, increased myotube forma-
tion, and hence accelerated differentiation (148). A spike in
intracellular Ca2 is required for the maturation of a num-
ber of precursor cell types (23), while low resting cytosolic
Ca2 is a feature in most mature cells. Studies of Xenopus
oocytes indicate that PMCA internalization, preventing
PMCA-mediated efflux, contributes towards the sustained
increase in cytosolic [Ca2] necessary for egg activation
during maturation (106). A similar spike in Ca2 is thought
to be required for neuronal cell differentiation, and it has
been shown that PMCA activity increases substantially in
PMCAs IN HUMAN DISEASE
1109Physiol Rev • VOL 97 • JULY 2017 • www.prv.org
 by 10.220.33.1 on June 20, 2017
http://physrev.physiology.org/
D
ow
nloaded from
 
line with PMCA2, 3, and 4 expressions as IMR-32 neu-
roblastoma cells become differentiated, postulated to al-
low for optimal Ca2 signaling in mature cells (377). In
contrast, PMCA expression is highly abundant in mega-
karyoblastoid precursor cells (primarily PMCA4) com-
pared with mature platelets (281), while expression and
activity also decrease during the differentiation process
in keratinocytes (75).
Hence, the PMCA may play a complex role in cellular mat-
uration, and there is a suggestion that cell-specific patterns
of PMCA expression may provide a signature for terminal
differentiation among different cell types. This has been put
forth following studies examining the expression of alter-
nate splice variants during differentiation of myogenic and
neuronal cells alongside fibroblasts, smooth muscle, and
endothelial cells, which have shown a switch from the “b”
splice variants of PMCA1 and 4 during differentiation to
also express isoforms 1c, 1d, and 4a and that this is unique
to the excitable cell types (86, 147).
2. PMCA during proliferation
A role for the PMCAs in proliferation has now been iden-
tified in a number of cell types. Of these, perhaps the best
defined is in the regulation of the vascular smooth muscle
cell (VSMC) cycle. Husain and colleagues (3, 165) have
shown that repression of PMCA1 expression in rat VSMCs
through the binding of transcription factor c-Myb to its
promoter region leads to a subsequent reduction in the rate
of PMCA-mediated Ca2 efflux, which results in the in-
crease in intracellular Ca2 required for G1/S stage transi-
tion in the cell cycle. Moreover, the authors (165) showed
that PMCA1 overexpression inhibited S phase entry and
reduced the rate of proliferation. The authors (4) have since
found an opposing role for PMCA4 in cell cycle progres-
sion, with VSMCs from PMCA4 knockout mice displaying
G1 phase arrest which could be rescued upon electropora-
tion of either PMCA4a or 4b splice variants. Each of these
splice variants appeared to regulate independent pathways
with PMCA4a suppressing the anti-proliferative AP-2 and
4b downregulating the cyclin-dependent kinase inhibitor
p15, while an isoform switch occurred from a 50:50 ratio in
normal vessels to PMCA4b being the predominant variant
following arterial injury (4). Interestingly studies of canine
VSMCs have found PMCA4a to be present only in prolif-
erating cell populations (2). Meanwhile, in contrast to
VSMCs, PMCA4 has been shown to be downregulated in
proliferating airway SMCs and inhibition to enhance pro-
liferation, whereas nonselective inhibition (and thus addi-
tionally of PMCA1) had the opposite effect (74).
In addition to its roles in arterial smooth muscle cells, the
actions of PMCA4 have recently been shown to mediate
VEGF-induced angiogenic signaling in vascular endothelial
cells (17). Baggott et al. (17) found PMCA4 to inhibit en-
dothelial cell migration and blood vessel formation through
suppression of calcineurin/NFAT signaling while also dem-
onstrating that PMCA4 knockout mice had improved
hindlimb perfusion following femoral artery ligation.
3. PMCA in cell death
Ca2 signaling plays a critical role in cell viability; a rise in
basal Ca2 can lead to mitochondrial dysfunction and ac-
tivate pro-apoptotic factors, while Ca2 overload may
cause cells to undergo necrosis (23, 271). As regulators of
global [Ca2]i and Ca
2-mediated signaling, the PMCAs
have been implicated in both necrotic and programmed cell
death in numerous cell types.
In some instances PMCA-mediated apoptosis is required
for normal physiological functions. For example, mice ex-
hibit a 95% reduction in PMCA2 expression in mammary
epithelial cells (which as we discuss elsewhere is greatly
elevated during lactation) as early as 24 h after weaning,
thus leaving the cells in a state of high Ca2, triggering
apoptosis and ultimately mammary gland involution (305,
384). Improper control of this process however, as evi-
denced by PMCA2 mutant deafwaddler mice, results in
apoptosis of mammary epithelial cells during pregnancy
(384). PMCA-dependent promotion of cell survival has also
been demonstrated in follicular granulosa cells, which
through a basic fibroblast growth factor-mediated increase
in PKC activity are able to upregulate PMCA1 expression
and Ca2 efflux, thus preventing apoptosis in response to
elevated [Ca2]i (287, 288). In line with this protective role,
antisense-mediated inhibition of PMCA1 and PMCA2, re-
spectively, in rat VSMCs and PC12 cells induces apoptosis
(32, 326).
PMCA’s role in regulating cell death is somewhat complex
however. A mutant form of PMCA4 which demonstrated
greatly reduced expression in L929 fibrosarcoma cells con-
ferred resistance to tumor necrosis factor-induced cell death
despite elevated cytosolic Ca2, thought to result from the
promotion of exocytosis of acidic lysosomes accumulating
in the cytoplasm (270). In addition, the PMCA is particu-
larly vulnerable to proteolysis, and it has consistently been
shown that in the early stages of apoptosis the autoinhibi-
tory COOH-terminal is cleaved from PMCA4 by caspase-3
leaving a properly targeted 120-kDa fragment active even in
the absence of calmodulin (279, 280, 282). In theory, this
would then increase Ca2 extrusion and protect cells from
overload; however, it appears that cleavage can eventually
impair PMCA activity. This has been witnessed in hepato-
cytes transfected with hepatitis B virus X protein, which
undergo apoptosis associated with increased PMCA4 cleav-
age by caspase-3, higher [Ca2]i, and mitochondrial abnor-
malities (68). The same is true during ischemic brain injury
in rats and in glutamate-treated cerebellar granule neurons,
which demonstrate caspase-1-induced cleavage of PMCA2
leading to impaired activity and apoptosis (337). Schwab et
al. (337) also determined that PMCA4 cleavage in nonex-
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citable CHO cells resulted in impaired Ca2 handling, Ca2
overload, and secondary necrosis.
The mechanisms through which the PMCA pump becomes
inactivated under these circumstances are unclear. One sim-
ple hypothesis would be that further cleavage would result
in proteolytic degradation and reduced expression. There is
also the suggestion that ATP depletion via mitochondrial
dysfunction impairs PMCA activity resulting in Ca2 over-
load and necrosis, as evidenced in pancreatic acinar cells
exposed to palmitoleic acid in a model of acute pancreatitis
(324). Further evidence that Ca2 overload and necrosis
occur as a result of reduced PMCA activity following ATP
depletion has been identified in epithelial cells exposed to
oxidative stress, where increased Na-K-ATPase activity
induced by elevated [Na]i effectively “steals” ATP from
the PMCA rendering the pump inactive (63). Similarly,
UVB irradiation-induced oxidative stress in human lens ep-
ithelial cells has been shown to reduce PMCA1 expression
and activity resulting in increased Ca2 and necrosis (403).
Thus it appears the PMCA plays a complex role in directing
cell death via apoptotic or necrotic pathways. This can be
highlighted by its regulation by the anti-apoptotic protein
Bcl-2; pancreatic acinar cells isolated from Bcl-2 knockout
mice demonstrate enhanced PMCA-mediated Ca2 clear-
ance and a resistance to oxidation or Ca2-induced necro-
sis, but increased apoptosis. Bcl-2 overexpression mean-
while was shown to impair Ca2 extrusion while PMCA
inhibition led to increases in necrosis in pancreatic cells
(118).
J. Role of PMCAs in Cancer
Regulation of the Ca2 signal can impact on many of the
typical hallmarks of cancer such as sustained proliferation,
resistance to cell death, and induction of angiogenesis (149,
354). This had led to the study of Ca2 handling compo-
nents during tumor development becoming an active field of
research in recent years, with the TRP channel family lead-
ing the way, and may offer a number of novel pharmaceu-
tical targets for the treatment of cancer (325). As we high-
lighted in the previous section, there is substantial evidence
that PMCA expression and activity, like that of TRP chan-
nels, also impacts on many of the cellular processes defining
tumorigenesis and progression. Indeed, first evidence for a
potential role for the PMCA came from analysis of the
expression of PMCA1 and 4 in human skin and lung fibro-
blastic cell lines following exposure to the oncogenic simian
virus 40 (SV40), both of which were found to be downregu-
lated (307). In this section we describe the expression
changes and roles of the PMCA to have currently been
identified in various cancers.
1. PMCA and breast cancer
As we discussed elsewhere in this review, changes in PMCA
expression and particularly that of isoform 2 are inextrica-
bly linked tomammary epithelial cell physiology, showing a
dramatic upregulation during lactation and its immediate
downregulation being essential for mammary gland involu-
tion upon weaning (303–305, 384). This highlights a po-
tentially critical role for the pumps in regulating cell sur-
vival. PMCA isoforms 1, 2, and 4 are all expressed in a
variety of human breast cancer cell lines (203), with
PMCA2 levels being up to 100-fold higher in tumorigenic
versus nontumorigenic human breast epithelial cell lines
(204). Similarly, PMCA1 demonstrates an approximately
threefold increase in expression in serum-starved MCF-7
breast cancer cells compared with control MCF-10A mam-
mary epithelial cells, while PMCA4 levels appear lower in
some cancerous cell lines compared with controls (203,
204).
Clinically, high levels of PMCA2 expression in breast tu-
mors correlate with increased tumor grade, resistance to the
chemotherapeutic drug docetaxel, and reduced 5-yr sur-
vival rates in breast cancer patients (169, 384). Each of
these studies examined the effects of PMCA2 overexpres-
sion in breast cancer cells, reporting decreases in [Ca2]i
and apoptosis as well as higher incidence, reduced latency,
and accelerated tumor growth when grown as xenografts in
immunocompromised mice (169, 384). In agreement with
this, crossing PMCA2-inactive mutant deafwaddler mice
with mouse mammary tumor virus (MMTV)-Neu mice in-
hibited tumor formation (169). Mechanistically, these ef-
fects may well be multifaceted. Jeong et al. (169) found
PMCA2 expression to correlate with human epidermal
growth factor receptor 2 (HER2) in breast tumors, and
through a physical interaction to regulate HER2 signaling
as well as its internalization and degradation upon PMCA2
knockdown. In addition, PMCA2 has been found to inter-
act with calcineurin in breast cancer cells, with overexpres-
sion leading to a reduction in NFAT transcriptional activity
(159) and disruption of the complex causing NFAT activa-
tion with a consequential upregulation in proapoptotic Fas
ligand expression, apoptosis, and increased cytotoxicity to
the chemotherapeutic agent paclitaxel (18).
There is evidence that PMCA1 and 4 may also play impor-
tant roles in signal regulation in breast cancer cells and that
these are isoform specific. Upregulation of PMCA4 has
been witnessed during induced differentiation of MCF-7
breast cancer cells alongside an increased rate of Ca2 clear-
ance (386). PMCA4 expression also increases during pro-
liferation in these cells, and antisense PMCA inhibition was
shown to result in reduced rates of proliferation while in-
creasing [Ca2]i and impairing PMCA-mediated Ca
2
clearance (205). Fewer cells were found to be in the S phase
and more in the G2/M phase of the cell cycle upon PMCA
inhibition, with the authors concluding slower transition
through this stage. Further experiments by the group, this
time in theMDA-MB-231 breast cancer cell line, have iden-
tified that PMCA1 primarily regulates bulk Ca2 extrusion
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in these cells and that knockdown of this isoform leaves
cells vulnerable to Ca2-induced necrotic cell death (81).
PMCA4 silencing, on the other hand, was found to enhance
apoptosis induced by Bcl-2 inhibition, likely through regu-
lation of NFB signaling.
Hence, there is evidence to suggest that inhibition of any of
the three PMCA isoforms expressed in breast cancer cells
may have the potential to be used as an anti-cancer therapy.
This may be highlighted by research conducted using a new
platinum-based compound [Pt(O,O0-acac)(g-acac)(DMS)],
which is highly cytotoxic to cisplatin-resistant MCF-7 cells
through inhibition of PMCA activity, thus raising [Ca2]i
and activating apoptotic pathways (255, 256). This may be
a promising avenue to explore, particularly in tumors resis-
tant to currently available chemotherapeutic agents.
2. PMCA and colorectal cancer
The finding that PMCA expression was altered during
breast cancer tumorigenesis prompted the question as to
whether this was also the case in other neoplastic cell types.
Both PMCA1 and 4 have been shown to be expressed in a
variety of human colon cancer cell lines, with isoform 1
predominating in undifferentiated cells (14, 311). During
induced or postconfluent differentiation however, there is a
marked upregulation of PMCA4 expression as well as en-
hanced PMCA-mediated Ca2 efflux (14, 15, 311). In con-
trast, differentiated colon tumors exhibit significantly lower
PMCA4 expression compared with healthy surrounding
tissue (15). Aung et al. (15) then went on to determine that
siRNA inhibition of PMCA4 did not alter HT-29 colon
cancer cell viability following apoptotic stimulation, while
overexpression led to a decrease in cell proliferation sug-
gesting that the postdifferentiation downregulation of
PMCA4 may facilitate tumor growth. In agreement with
these findings, an examination of PMCA4 protein in nor-
mal mucosa compared with varying grades of colon tumor
has found reduced levels only in high grade adenoma, ade-
nocarcinoma, and lymph node metastasis indicating a po-
tential role in tumor progression (319). Meanwhile, rectal
tumors display elevated PMCA4 expression compared with
normal mucosa (133).
3. PMCA and other cancers
In addition to the more extensively defined roles in breast
and colon cancer, an association has also been found be-
tween the PMCAs and tumors in a number of other tissues.
PMCA1 has been found to be downregulated in oral squa-
mous cell carcinoma and premalignant lesions, a possible
result of increased methylation (322). Conversely, PMCA
expression appears higher in mouse AS-30D hepatoma cells
comparedwith normal liver, a pattern similar to that seen in
regenerating hepatic cells (90). In addition, evidence that
the PMCAs may be a potential therapeutic target for che-
motherapy-resistant cancers has been found in two further
cell types. First, PMCA1 expression is increased in cisplatin-
resistant human ovarian adenocarcinoma cells compared
with cisplatin-sensitive cells (348), and second, the resis-
tance to cell death conferred upon pancreatic cancer cells by
a switch in metabolism from mitochondrial to glycolytic
pathways can be reversed by inhibiting glycolysis, an effect
which leads to PMCA inhibition, Ca2 overload, and cell
death (167). Hence, although the field is still in its infancy,
the identified roles for different PMCA isoforms in regulat-
ing tumorigenesis, progression, and survival in various tis-
sues may lend themselves towards targeting for the treat-
ment of cancers in specific cell types.
V. CONCLUSIONS
The ubiquitous nature of PMCA expression combined with
the tissue-specific distribution of the four isoforms provide
an adaptable toolkit to control intracellular Ca2 dynamics
throughout the body. As regulators of bulk Ca2 transport
they are critical in the maintenance of desirable serum ionic
balance for tissue mineralization from embryonic develop-
ment through to adulthood, as well as influencing processes
such as fertilization, smooth muscle tone, and cell survival.
Meanwhile, as binding partners they are able to direct
Ca2-dependent signaling to regulate a plethora of physio-
logical processes from sensory transmission to cellular
growth. Through genome-wide screening and the use of
animal models, specific roles for each isoform have now
been defined in the development and progression of a
large number of human diseases affecting the cardiovas-
cular, nervous, and musculoskeletal systems as well as in
the fields of cancer, endocrinology, and infectious dis-
ease. Given the widespread spatiotemporal expression
pattern of the PMCAs, it is perhaps surprising that mu-
tating or knocking out a particular isoform reveals a role
localized to a particular tissue. However, it is likely that
the specificity of action is dictated through a combination
of isoform/splice variant, interaction partner, and local
Ca2 requirements. It is the cell-specific functions of
these pumps combined with their nature as membrane-
bound ATPases that may therefore make them suitable
and druggable targets for the development of novel ther-
apeutic strategies in wide-ranging fields including contra-
ception, hypertension, cardiac hypertrophy, neurodegen-
eration, malaria, and cancer.
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